WEST Search History

Hide Items Restore Clear Cancel

DATE: Tuesday, October 19, 2004

| Hide? | Set Name | Query | Hit Count |
|-------|----------------|---------------------------------------|----------------|
| | DB = PGPB, USP | T,EPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR | =YES; $OP=ADJ$ |
| | L2 | coolidge-thomas-r\$.in. | 26 |
| | L1 | Ehlers-mario-r\$-W\$.in. | 3 |

END OF SEARCH HISTORY

Hit List

Generate OACS Generate Collection Print Fwd Refs **Bkwd Refs** Clear

Search Results - Record(s) 1 through 26 of 26 returned.

1. Document ID: US 20040002454 A1

Ising default format because multiple data bases are involved.

L2: Entry 1 of 26

File: PGPB

Jan 1, 2004

GPUB-DOCUMENT-NUMBER: 20040002454

GPUB-FILING-TYPE: new

OCUMENT-IDENTIFIER: US 20040002454 A1

ITLE: Treatment of acute coronary syndrome with GLP-1

UBLICATION-DATE: January 1, 2004

NVENTOR-INFORMATION:

IAME CITY

STATE

COUNTRY

RULE-47

Coolidge, Thomas R.

Falls Village

CT US

Chlers, Mario

Lincoln

NE

US

S-CL-CURRENT: 514/12

| 1 | Full | | itle Uitation | Front | Review | Classification | Date | Reference | sequences | Attachments | Claims | KOUNC | Draw, Desc | Image | |
|---|------|--------|-----------------|-------|---------|----------------|----------|-----------|-----------|-------------|--------|-------------------------|------------|-------|--|
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | ****** | | | | | <u> </u> | | | | | *********************** | | | |
| | | | | | | | | | | | | | | | |
| | | 2. | Document I | D: U | S 20030 | 0073626 A | .1 | | | | | | | | |

L2: Entry 2 of 26

File: PGPB

Apr 17, 2003

GPUB-DOCUMENT-NUMBER: 20030073626

GPUB-FILING-TYPE: new

OCUMENT-IDENTIFIER: US 20030073626 A1

ITLE: Compositions and methods for treating peripheral vascular disease

UBLICATION-DATE: April 17, 2003

NVENTOR-INFORMATION:

JAME CITY

STATE

RULE-47

Hathaway, David R.

Lincoln

NE

US

COUNTRY

Coolidge, Thomas R.

Falls Village

CT

US

S-CL-CURRENT: <u>514/12</u>; <u>424/722</u>, <u>424/94.4</u>, <u>514/18</u>, <u>514/23</u>, <u>514</u>/419, 514/458

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KMC Draw Desc Image

☐ 3. Document ID: US 20020147131 A1

L2: Entry 3 of 26

File: PGPB

Oct 10, 2002

GPUB-DOCUMENT-NUMBER: 20020147131

GPUB-FILING-TYPE: new

OCUMENT-IDENTIFIER: US 20020147131 A1

ITLE: Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused

keletal muscle tissue

UBLICATION-DATE: October 10, 2002

NVENTOR-INFORMATION:

IAME

CITY

STATE

COUNTRY

RULE-47

Coolidge, Thomas R.

Falls Village

CT

US

Chlers, Mario R.W.

Lincoln

NE

US

S-CL-CURRENT: 514/2; 530/308

| Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWC | Draw Desc | Image |
|------|-------|----------|-------|--------|----------------|------|-----------|-----------|-------------|--------|--|-----------|-------|
| | | | | | | | | • . | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | ······································ | | |

4. Document ID: US 20020146405 A1

L2: Entry 4 of 26

File: PGPB

Oct 10, 2002

GPUB-DOCUMENT-NUMBER: 20020146405

GPUB-FILING-TYPE: new

OCUMENT-IDENTIFIER: US 20020146405 A1

ITLE: Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide

UBLICATION-DATE: October 10, 2002

NVENTOR-INFORMATION:

IAME

CITY

STATE

COUNTRY

RULE-47

Coolidge, Thomas R.

Falls Village

CT

US

Chlers, Mario

Lincoln

NE

US

S-CL-CURRENT: <u>424/94.61</u>

| Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KMC | Draw, Desc | Image |
|--|---------------------------------------|-----------|-------|---|--|-------------------------------|-----------|---|--|--------|--|------------|-------------|
| | | | | | | | | | | | | | |
| ************************************** | · · · · · · · · · · · · · · · · · · · | - <u></u> | | *************************************** | ······································ | est destruction of the second | | *************************************** | ************************************** | | ······································ | | |

5. Document ID: US 20020107206 A1

L2: Entry 5 of 26

File: PGPB

Aug 8, 2002

GPUB-DOCUMENT-NUMBER: 20020107206

GPUB-FILING-TYPE: new

OCUMENT-IDENTIFIER: US 20020107206 A1

Record List Display

TITLE: Treatment of acute coronary syndrome with GLP-1

PUBLICATION-DATE: August 8, 2002

INVENTOR-INFORMATION:

NAME

CITY

STATE

COUNTRY

RULE-47

Coolidge, Thomas R.

Falls Village

CT

US

Ehlers, Mario

Lincoln

NE

US

JS-CL-CURRENT: 514/21

| Full | Т | tle Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KOMC | Drawu Desc | Image |
|------|--------------|--|--|---|----------------|---------------------------------|-----------|-----------|---|--------|------|------------|--|
| | | | | | | | | | | | | | |
| | ************ | ······································ | ······································ | *************************************** | <u></u> | 7870-0007- 7 0730000 | • | | *************************************** | | | | ~************************************* |
| | 5. | Document | ID: U | JS 2002 | 0055460 A | 1 | | | | ٠ | | | |

L2: Entry 6 of 26

File: PGPB

May 9, 2002

PGPUB-DOCUMENT-NUMBER: 20020055460

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020055460 A1

FITLE: Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused

cissue

PUBLICATION-DATE: May 9, 2002

INVENTOR-INFORMATION:

NAME

CITY

STATE

COUNTRY

RULE-47

Coolidge, Thomas R.

Falls Village

CT

US

Ehlers, Mario R.W.

Lincoln

ΝE

US

JS-CL-CURRENT: <u>514/2</u>; <u>514/23</u>, <u>514/53</u>

| Full Title Citation Front Review Classi | fication Date Reference Sequences Attachments | Claims KMC Draw Desc Image |
|---|---|--|
| | | |
| ☐ 7. Document ID: US 6706689 E | 32 | ************************************** |
| L2: Entry 7 of 26 | File: USPT | Mar 16. 2004 |

JS-PAT-NO: 6706689

DOCUMENT-IDENTIFIER: US 6706689 B2

FITLE: Treatment of acute coronary syndrome with GLP-1

DATE-ISSUED: March 16, 2004

INVENTOR-INFORMATION:

NAME

STATE

ZIP CODE

COUNTRY

Coolidge; Thomas R.

Falls Village

CT

Ehlers; Mario

Lincoln

CITY

NE

JS-CL-CURRENT: 514/12; 514/2

Full Title Citation Front Review Classification Date Reference Complement Augustination Claims KMC Draw Desc Image ☐ 8. Document ID: US 6429197 B1

L2: Entry 8 of 26

File: USPT

Aug 6, 2002

JS-PAT-NO: 6429197

OCUMENT-IDENTIFIER: US 6429197 B1

ITLE: Metabolic intervention with GLP-1 or its biologically active analogues to improve the

unction of the ischemic and reperfused brain

DATE-ISSUED: August 6, 2002

INVENTOR-INFORMATION:

CITY

STATE

ZIP CODE

COUNTRY

Coolidge; Thomas R.

NAME

Falls Village

CT

Ehlers; Mario R. W.

Lincoln

NE

Full Title Citation Front Review Classification Date Reference Sequencial Additionalist Claims KMC Draw Desc Image

9. Document ID: US 6284725 B1

L2: Entry 9 of 26

File: USPT

Sep 4, 2001

JS-PAT-NO: 6284725

OCUMENT-IDENTIFIER: US 6284725 B1

TITLE: Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused

issue

DATE-ISSUED: September 4, 2001

NVENTOR-INFORMATION:

CITY

ZIP CODE STATE

COUNTRY

Coolidge; Thomas R.

Falls Village

CT

Ehlers; Mario R. W.

Lincoln

NE

IS-CL-CURRENT: 514/2; 424/185.1, 514/12, 530/300, 530/324

Full Title Citation Front Review Classification Date Reference Coccurred Microbinetts Claims KMIC Draw Desc Image

☐ 10. Document ID: US 6127150 A

L2: Entry 10 of 26

File: USPT

Oct 3, 2000

S-PAT-NO: 6127150

OCUMENT-IDENTIFIER: US 6127150 A

ITLE: Purification cloning of peptides

ATE-ISSUED: October 3, 2000

NVENTOR-INFORMATION:

CITY STATE ZIP CODE COUNTRY IAME

Coolidge; Thomas R. Falls Village CTWalton NE lagner; Fred

Gainesville an Heeke; Gino FL

Schuster; Sheldon M. Gainesville FL

Stout; Jay Lincoln NE

NE Mylie; Dwane E. Lincoln

S-CL-CURRENT: 435/69.7; 435/195, 435/68.1, 435/69.4, 435/69.5, 435/70.1, 530/350, 530/351, 30/385, 530/399, 530/412, 530/415

| Full | Title | Citation | Front | Review | Classification | Date | Reference | | Claims | KWIC | Draw Desc | Image |
|------|-------|--|-------|---------|----------------|------|--|--|--------|-------|-----------|-------|
| | | | | | | | | | | | | |
| · | | ////////////////////////////////////// | ~~~ | | | |).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | | | ***** | ······· | |
| _ , | 11 F | \ | 4 ID. | 110 574 | 1606 A | | | | | | | |

11. Document ID: US 5/41686 A

L2: Entry 11 of 26

File: USPT

Apr 21, 1998

S-PAT-NO: 5741686

OCUMENT-IDENTIFIER: US 5741686 A

* See image for Certificate of Correction **

ITLE: Exopeptidase catalyzed site-specific bonding of supports, labels and bioactive agents to roteins

ATE-ISSUED: April 21, 1998

NVENTOR-INFORMATION:

JAME CITY ZIP CODE STATE COUNTRY Nagner; Fred W. Walton NECoolidge; Thomas R. Falls Village CT

Nylie; Dwane E. Lincoln NESchuster; Sheldon M. Gainesville FL

∟ewis; William Lincoln NE Stout; Jay Lincoln

S-CL-CURRENT: $\frac{435}{188}$; $\frac{435}{176}$, $\frac{435}{177}$, $\frac{435}{180}$, $\frac{435}{181}$, $\frac{435}{183}$, $\frac{435}{41}$, $\frac{436}{524}$, $\frac{436}{528}$,

36/531, 436/532, 436/547 , 514/2, 530/402, 530/811, 530/812, 530/815, 530/816

| Full | Title | Citation | Front | Review | Classification | Date | Reference | The second second | Claims | KOMC | Draw Desc | Impae |
|------|-------|----------|-------|--------|----------------|------|-----------|-----------------------|--------|------|--------------|------------|
| | | | | | | | | | | | D 100% D 200 | i illage (|
| | | | | | | | | | | | | |
| | | | | * | | | | | | | | |

NE

12. Document ID: US 5700775 A

cord List Display,

L2: Entry 12 of 26

File: USPT

Dec 23, 1997

SE

PAT-NO: 5700775

UMENT-IDENTIFIER: US 5700775 A

LE: Method and treatment composition for decreasing patient time in catabolic state after umatic injury

E-ISSUED: December 23, 1997

ENTOR-INFORMATION:

CITY STATE ZIP CODE COUNTRY

tniak; Mark K. S-165 65 Hasselby

olidge; Thomas R. Falls Village 06031 CTcker; Robert R. Omaha NE68144

gner; Fred W. Walton NE 68461

CL-CURRENT: 514/12; 514/21

| Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Image |
|------|-------|----------|-------|--------|----------------|------|-----------|--------|------|-----------|-------|
| | | | | | | | | | | | |
| | | | | | | | | | | | |

☐ 13. Document ID: US 5656456 A

L2: Entry 13 of 26

File: USPT Aug 12, 1997

PAT-NO: 5656456

CUMENT-IDENTIFIER: US 5656456 A

See image for Certificate of Correction **

LE: Chemical method for selective modification of the N- and/or C-terminal amino d .alpha.-carbon reactive group of a recombinant polypeptide or a portion thereof

E-ISSUED: August 12, 1997

ENTOR-INFORMATION:

ΜE CITY STATE ZIP CODE COUNTRY

out; Jay Lincoln NE

gner; Fred W. Walton NE

olidge; Thomas R. Falls Village CTMA

lmquist; Bart Waltham

CL-CURRENT: 435/69.1

| Full | Ti | tle | Citation | Front | Review | Classification | Date | Reference | 259 in the Action | | Claims | KMC | Draw Desc | Image |
|------|---------------|--|----------|--|--|----------------|--|-----------|---|---|-------------|-----|-----------|-------|
| | | | | | • | | | • | | | | | | |
| | ************* | ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | | ************************************** | ************************************** | v | ······································ | | *************************************** | *************************************** | | ··· | | |

☐ 14. Document ID: US 5635371 A

L2: Entry 14 of 26 File: USPT Jun 3, 1997

PAT-NO: 5635371

UMENT-IDENTIFIER: US 5635371 A

See image for Certificate of Correction **

LE: Chemical method for selective modification of the N- and/or C-terminal amino d .alpha.-carbon reactive group of a recombinant polypeptide or a portion thereof

E-ISSUED: June 3, 1997

ENTOR-INFORMATION:

CITY

STATE ZIP CODE COUNTRY

out; Jay gner; Fred W. Lincoln Walton

NE

olidge; Thomas R.

Falls Village

CT

NE

lmquist; Bart

Waltham

MA

File: USPT

CL-CURRENT: 435/69.1

| Fu | ll Tit | e Citation I | Front | Review | Classification | Date | Reference | | Claims | KWIC | Drawu Desc | Image |
|----|----------|--------------|-------|--------|----------------|------|-----------|--|--|------|------------|-------|
| | | | | | | | | | | | • | • |
| | 15. | Document | ID: | US 559 | 5887 A | | | | ************************************** | | | |

PAT-NO: 5595887

L2: Entry 15 of 26

CUMENT-IDENTIFIER: US 5595887 A

See image for Certificate of Correction **

LE: Purification directed cloning of peptides using carbonic anhydrase as the affinity nding segment

E-ISSUED: January 21, 1997

ZENTOR-INFORMATION:

CITY ZIP CODE ΜE STATE COUNTRY

olidge; Thomas R.

Falls Village

CT

Jan 21, 1997

gner; Fred n Heeke; Gino Walton

NEFL

huster; Sheldon M.

Gainesville Gainesville

FL

out; Jay

lie; Dwane E.

Lincoln Lincoln

NE NE

-CL-CURRENT: <u>435/69.7</u>; <u>435/68.1</u>

☐ 16. Document ID: US 5464759 A

L2: Entry 16 of 26

File: USPT

Nov 7, 1995

PAT-NO: 5464759

CUMENT-IDENTIFIER: US 5464759 A

TLE: Sequential oligonucleotide syntheses using immunoaffinity techniques

TE-ISSUED: November 7, 1995

VENTOR-INFORMATION:

| AME | CITY | STATE | ZIP CODE | COUNTRY |
|---------------------|---------------|-----------|----------|---------|
| polidge; Thomas R. | Falls Village | CT | | |
| ewis; William | Lincoln | NE | | |
| chuster; Sheldon M. | Gainesville | ${	t FL}$ | | |
| cout; Jay | Lincoln | NE | | |
| an Heeke; Gino | Gainesville | ${	t FL}$ | | |
| ylie; Dwane | Lincoln | NE | | |
| agner; Fred W. | Walton | NE | | • |

-CL-CURRENT: $\underline{435}/\underline{91.2}$; $\underline{435}/\underline{6}$, $\underline{514}/\underline{44}$, $\underline{536}/\underline{22.1}$, $\underline{536}/\underline{23.1}$, $\underline{536}/\underline{24.1}$, $\underline{536}/\underline{24.2}$, $\underline{536}/\underline{24.31}$, 6/24.32, 536/25.3

| Full Title Citation Front Review Classification | Date Reference Santing C. Estate Control | laims KWMC Draww Desc Image |
|---|--|---------------------------------|
| | | |
| | | |
| | | |
| ☐ 17. Document ID: US 5279954 A | | |
| L2: Entry 17 of 26 | File: USPT | Jan 18, 1994 |

-PAT-NO: 5279954

CUMENT-IDENTIFIER: US 5279954 A

TLE: Exopeptidase catalyzed site-specific bonding of supports, labels and bioactive agents to oteins

TE-ISSUED: January 18, 1994

IVENTOR-INFORMATION:

| AME | CITY | STATE | ZIP CODE | COUNTRY |
|---------------------|---------------|-----------|----------|---------|
| agner; Fred W. | Walton | NE | | |
| oolidge; Thomas R. | Falls Village | CT | | |
| ylie; Dwane E. | Lincoln | NE | | |
| chuster; Sheldon M. | Gainesville | ${	t FL}$ | | |
| ewis; William | Lincoln | NE | | |
| tout; Jay | Lincoln | NE | | |
| • | | | | |

-CL-CURRENT: $\underline{435}/\underline{176}$; $\underline{435}/\underline{177}$, $\underline{435}/\underline{180}$, $\underline{435}/\underline{181}$, $\underline{436}/\underline{524}$, $\underline{436}/\underline{528}$, $\underline{436}/\underline{531}$, $\underline{436}/\underline{532}$, $\underline{530}/\underline{811}$, <u>0/812</u>, <u>530/815</u>, <u>530/816</u>

| Full Title Citation | Front Review Classif | cation Date Reference | CI | aims KWMC | Draw. Desc Image |
|---|--|-----------------------|---|-----------|--------------------|
| | | | | | |
| *************************************** | en e | | *************************************** | | |

☐ 18. Document ID: US 5234820 A

L2: Entry 18 of 26

File: USPT

Aug 10, 1993

JS-PAT-NO: 5234820

DOCUMENT-IDENTIFIER: US 5234820 A

FITLE: Exopeptidase catalyzed site-specific bonding of supports, labels and bioactive agents to

oroteins

DATE-ISSUED: August 10, 1993

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Wagner; Fred W. Walton NE

Coolidge; Thomas R. Falls Village CT

Schuster; Sheldon M. Gainesville FL

Stout; Jay Lincoln NE

Stout; Jay Lincoln NE Wylie; Dwane E. Lincoln NE

Breddam; Klaus Glostrup DK

Lewis; William Lincoln NE

JS-CL-CURRENT: <u>435/41</u>; <u>435/181</u>, <u>435/7.1</u>, <u>435/7.92</u>, <u>436/532</u>, <u>436</u>/544, 530/816

| Fu | ll Ti | le Citation | Front | Review | Classification | Date | Reference | | Clain | s KWMC | Draw, Desc | Image |
|----|-------|-------------|-------|----------|----------------|------|--|--|-------|--------|------------|--|
| | | | | | | | | | | | | |
| | 10 | Documer | , TT | T TO 500 | 1706 | | ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ | ************************************** | | | | ************************************** |

13 19. Document 1D: US 5221736 A

L2: Entry 19 of 26

File: USPT

Jun 22, 1993

JS-PAT-NO: 5221736

OCCUMENT-IDENTIFIER: US 5221736 A

** See image for Certificate of Correction **

FITLE: Sequential peptide and oligonucleotide syntheses using immunoaffinity techniques

DATE-ISSUED: June 22, 1993

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Coolidge; Thomas R.Falls VillageCTLewis; WilliamLincolnNESchuster; Sheldon M.GainesvilleFLWylie; DwaneLincolnNE

Wagner; Fred W. Walton NE Stout; Jay Lincoln NE

van Heeke; Gino Gainesville FL

JS-CL-CURRENT: $\underline{536/25.31}$; $\underline{435/4}$, $\underline{435/5}$, $\underline{435/6}$, $\underline{435/7.5}$, $\underline{435/7.8}$, $\underline{435/803}$, $\underline{435/810}$, $\underline{435/91.5}$, $\underline{436/518}$, $\underline{436/531}$, $\underline{436/824}$, $\underline{530/387.1}$, $\underline{536/26.71}$

Full Title Citation Front Review Classification Date Reference Supplicated Attachinguist Claims KWIC Draw Desc Image

☐ 20. Document ID: EP 1419783 A2

L2: Entry 20 of 26

File: EPAB

May 19, 2004

UB-NO: EP001419783A2

OCUMENT-IDENTIFIER: EP 1419783 A2

ITLE: Use of a composition comprising an exendin or a compound derived therefrom and a

harmaceutical carrier

PUBN-DATE: May 19, 2004

INVENTOR-INFORMATION:

VAME

GOKE, BURKHARD

BYRNE, MARIA

COOLIDGE, THOMAS R

COUNTRY

DE

US

US

NT-CL (IPC): A61 K 38/22; A61 P 3/00

UR-CL (EPC): A61K038/22

| Full Tit | tle Citation Front Review Classification | Date Reference Septimoses Michiganics Claims KMC Draw Desc Image |
|--|--|--|
| | | |
| \$677758014886777887768477788777777787777777 | | |
| □ 21. | Document ID: EP 1170300 A1 | |

L2: Entry 21 of 26

File: EPAB

Jan 9, 2002

PUB-NO: EP001170300A1

OCUMENT-IDENTIFIER: EP 1170300 A1

TITLE: Method for modification of recombinant polypeptides

OUBN-DATE: January 9, 2002

NVENTOR-INFORMATION:

MAI COUNTRY

STOUT, JAY

US

WAGNER, FRED W

US

COOLIDGE, THOMAS R

US

HOLMQUIST, BART

US

NT-CL (IPC): C07 K 1/00; C07 K 1/06

CUR-CL (EPC): C07K001/107; C07K001/107, C07K005/10 , C07K007/18 , C07K014/47 , C07K014/475 ,

:07K014/60

| Fi | ااد | Title | Citation | Front | Review | Classification | Date | Reference | | CI | aims | KWMC | Draw Desc | Image |
|-----|-----|-------|----------|-------|---------|----------------|------|--------------------------------|--|------|------|---|-----------|-------|
| | | | | | , | | | | | | | | | |
| r=: | ^/ | ^ 7 | | . TD | 1110 00 | 47171 41 | | ****************************** | ······································ | | | *************************************** | | , |

Li 22. Document ID: WO 9947161 A1

L2: Entry 22 of 26

File: EPAB

Sep 23, 1999

JB-NO: WO009947161A1

CUMENT-IDENTIFIER: WO 9947161 A1

TLE: HUMAN APPETITE CONTROL BY GLUCAGON-LIKE PEPTIDE RECEPTOR BINDING COMPOUNDS

JBN-DATE: September 23, 1999

IVENTOR-INFORMATION:

AME

COUNTRY

OKE, BURKHARD

EGLINGER, CHRISTOPH

DE CH

OOLIDGE, THOMAS R

US

NT-CL (IPC): A61 K 38/26; C07 K 14/605 JR-CL (EPC): C07K014/605; A61K038/26

| Fu | ıII | Title Citation | Front | Review | Classification | Date | Reference | 177.4 177.1 177.1 177.1 177.1 177.1 177.1 177.1 177.1 177.1 177.1 177.1 177.1 177.1 177.1 177.1 177.1 177.1 1 | - page 15 | Claims | KWC | Draww Desc | Image |
|----|-----|------------------|--------|--------|----------------|------|-----------|---|--|--------|-----|------------|-------|
| | 23 | Documer | ıt ID. | WO 95 | 03321 A1 | | | | ······································ | | | | |

1 23. Document ID: WO 9303321 A1

L2: Entry 23 of 26

File: EPAB

Feb 2, 1995

Mar 30, 1994

JB-NO: WO009503321A1

OCUMENT-IDENTIFIER: WO 9503321 A1

ITLE: METHOD FOR ENDOMODIFICATION OF PROTEINS

JBN-DATE: February 2, 1995

NVENTOR-INFORMATION:

AGNER, FRED W

AME

COUNTRY

OOLIDGE, THOMAS R

NT-CL (IPC): C07 K 1/13; C07 K 1/00; C07 K 1/107; C12 P 21/02

UR-CL (EPC): C07K001/00; C07K001/107, C07K001/107 , C07K001/13 , C12P021/02

| F | ull Ti | tle Citation | Front | Review | Classification | Date | Reference | and the same of th | Claims | KWMC | Drawu Desc | lmage |
|---|--------|--------------|--------|--------|----------------|------|-----------|--|--------|------|------------|-------|
| *************************************** | | | | | | | | | | | | · |
| | 24. | Documer | nt ID: | EP 589 | 487 A1 | | | | | | | |

File: EPAB

L2: Entry 24 of 26

UB-NO: EP000589487A1 OCUMENT-IDENTIFIER: EP 589487 A1

ITLE: Monoclonal antibodies for small organic molecules.

UBN-DATE: March 30, 1994

NVENTOR-INFORMATION:

IAME

COUNTRY

AGNER, FRED W

US

CLIE, DWANE E
US
CHUSTER, SHELDON M
US
COLIDGE, THOMAS R
US
ONG, PILL-SOON
US
ARKER, WILLIAM
US

T-CL (IPC): C12P 21/08; C12N 5/16; G01N 33/53; G01N 33/84; C07K 15/28

R-CL (EPC): C07K016/44; G01N033/53, G01N033/84

| Full | Titl | e Citation Front | Review | Classification | Date | Reference | | | Claims | KWMC | Draw, Desc | Image |
|---|------|--|--------|----------------|---|-----------|--|---|------------------------|------|---|-------|
| | | | | | | | | | | | | |
| *************************************** | ···· | ······································ | | | *************************************** | | ······································ | *************************************** | inii inio minio maisii | | ••••••••••••••••••••••••••••••••••••••• | · |
| | 25. | Document ID: | WO 94 | 01451 A2 | | | | | | | | |

2. Entry 25 of 26

L2: Entry 25 of 26

File: EPAB

Jan 20, 1994

B-NO: WO009401451A2

CUMENT-IDENTIFIER: WO 9401451 A2

TLE: METHOD FOR MODIFICATION OF RECOMBINANT POLYPEPTIDES

BN-DATE: January 20, 1994

WENTOR-INFORMATION:

AME COUNTRY
FOUT, JAY US
AGNER, FRED W US
COLIDGE, THOMAS R US
COLMQUIST, BART US

TT-CL (IPC): C07K 1/00; C07K 3/08

R-CL (EPC): C07K001/00; C07K001/00, C07K001/107 , C07K001/107 , C07K001/12 , C07K005/10 ,

7K007/18 , C07K014/47 , C07K014/475 , C12N015/62

| | -ull | Title | Citation | Front | Review | Classification | Date | Reference | | Claims | KWIC | Drawu Desc | Image |
|-----|------|-------|----------|-------|--------|----------------|------|-----------|----------|---|------|------------|-------|
| | | | | | | | | | | | | | |
| | | | | | | · | | | | <i>(6.4.</i> 0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0. | | | |
| | 26 | 5. D | ocumen | t ID: | WO 90 | 10709 A2 | | | | | | | |
| L2: | Ent: | ry 26 | of 26 | 5 | | | | Fi: | le: EPAB | | | Sep 20, | 1990 |

B-NO: WO009010709A2

CUMENT-IDENTIFIER: WO 9010709 A2

TLE: MONOCLONAL ANTIBODIES FOR SMALL MOIETIES, METHODS THEREFOR

JBN-DATE: September 20, 1990

WENTOR-INFORMATION:

AME COUNTRY
AGNER, FRED W US
YLIE, DWANE E US
CHUSTER, SHELDON M US
COLIDGE, THOMAS R US

ONG, PILL-SOON ARKER, WILLIAM

US US

S-CL-CURRENT: 435/7.92; 435/332, 435/FOR.111, 530/388.9 NT-CL (IPC): C12N 5/16; C12P 21/08; G01N 33/53; G01N 33/577 UR-CL (EPC): C07K016/44; G01N033/543, G01N033/68, G01N033/84

| e Citation Front Review Classification Date Reference supported to the Classification Date Reference | ms KWMC Draw. Desc Clip Im |
|--|----------------------------|
| ear Generate Collection Print Fwd Refs Bkwd Refs | Generate OACS |
| Cal Sericiale Collection Fillit PWU Reis DRWU Reis | Generale OACS |
| Term | Documents |
| COOLIDGE-THOMAS-R\$ | 0 |
| | |
| COOLIDGE-THOMAS-R | 26 |
| COOLIDGE-THOMAS-R COOLIDGE-THOMAS-R\$.INPGPB,USPT,EPAB,DWPI,TDBD. | 26 |

Display Format: - Change Format

Previous Page Next Page Go to Doc#

Hit List

Clear Generate Collection **Print** Fwd Refs Bkwd Refs Generate OACS

Search Results - Record(s) 1 through 3 of 3 returned.

1. Document ID: US 20040033532 A1

Using default format because multiple data bases are involved.

L1: Entry 1 of 3

File: PGPB

Feb 19, 2004

Aug 6, 2002

PGPUB-DOCUMENT-NUMBER: 20040033532

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040033532 A1

FITLE: Use of three-dimensional crystal structure coordinates to design and synthesize domainselective inhibitors for angiotensin-converting enzyme (ACE)

PUBLICATION-DATE: February 19, 2004

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY RULE-47

Ehlers, Mario R. W. Mercer Island Holmquist, Barton

WA US Eagle NEUS

JS-CL-CURRENT: <u>435/7.1;</u> 702/<u>19</u>

| Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Drawi Desc | Image |
|--|-------|----------|---|---------|----------------|------|-----------|---|-------------|---|---|------------|--|
| | | | | | | | | | | | | | <u> </u> |
| ······································ | | | *************************************** | | | | | | | | | | |
| | | | | ~ | | | | *************************************** | | *************************************** | *************************************** | | ·///////////////////////////////////// |
| 2 . | . Do | cument | ID: U | JS 6429 | 197 B1 | | | | | | | | |
| | | | | | | | | | | | | | |

JS-PAT-NO: 6429197

DOCUMENT-IDENTIFIER: US 6429197 B1

FITLE: Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain

DATE-ISSUED: August 6, 2002

INVENTOR - INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Coolidge; Thomas R. Falls Village CTEhlers; Mario R. W. Lincoln NE

Full Title Citation Front Review Classification Date Reference Conscious

☐ 3. Document ID: US 6284725 B1

L1: Entry 3 of 3

File: USPT

Sep 4, 2001

JS-PAT-NO: 6284725

OCUMENT-IDENTIFIER: US 6284725 B1

TITLE: Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused

issue

ATE-ISSUED: September 4, 2001

NVENTOR-INFORMATION:

VAME

CITY

STATE

ZIP CODE

COUNTRY

Coolidge; Thomas R.

Falls Village

CT

Ehlers; Mario R. W.

Lincoln

NE

JS-CL-CURRENT: <u>514/2</u>; <u>424/185.1</u>, <u>514/12</u>, <u>530/300</u>, <u>530/324</u>

| Title Citation Front Review Classification Date Reference Concention Allockments | Claims KMMC Draw Desc I |
|--|-------------------------|
| | |
| Clear Generate Collection Print Fwd Refs Bkwd Refs | Generate OACS |
| Term | Documents |
| EHLERS-MARIO-R\$-W\$ | 0 |
| EHLERS-MARIO-R-W | 3 |
| EHLERS-MARIO-R\$-W\$.INPGPB,USPT,EPAB,DWPI,TDBD. | 3 |
| (EHLERS-MARIO-R\$-W\$.IN.).PGPB,USPT,EPAB,DWPI,TDBD. | 3 |

Display Format: |-

Change Format

Previous Page

Next Page

Go to Doc#

WEST Search History

Hide Items Restore Clear Cancel

ATE: Tuesday, October 19, 2004

| lide? | <u>Set</u> Name | Query | Hit Count |
|-------|--------------------|---|--------------|
| | DB=PC | SPB,USPT,EPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YES; OP=ADJ | |
| | L4 | ((glucagon same like same peptide adj 1) or GLP-1) and reperfusion and ischemia and tissue adj damage | 30 |
| | L3 | ((glucagon same like same peptide adj 1) or GLP-1) and reperfusion and ischemia | 81 |
| | L2 | coolidge-thomas-r\$.in. | 26 |
| | L1 | Ehlers-mario-r\$-W\$.in. | 3 |

ND OF SEARCH HISTORY

Hit List

Clear Generate Collection Print **Fwd Refs Bkwd Refs** Generate OACS

Search Results - Record(s) 1 through 30 of 30 returned.

1. Document ID: US 20040156859 A1

ing default format because multiple data bases are involved.

L4: Entry 1 of 30

Aug 12, 2004

PUB-DOCUMENT-NUMBER: 20040156859

PUB-FILING-TYPE: new

CUMENT-IDENTIFIER: US 20040156859 A1

TLE: Pulmonary delivery for bioconjugation

BLICATION-DATE: August 12, 2004

VENTOR-INFORMATION:

| ME | CITY | STATE | COUNTRY | RULE-47 |
|--------------------|------------------|-------|---------|---------|
| rin, Alan M. | Moraga | CA | US | |
| eser, Angelica | Montreal | CA | CA | |
| bitaille, Martin | Granby | | CA | |
| lner, Peter G. | Los Altos Hills | | US | |
| idon, Dominique P. | Ville Mont-Royal | | CA | |
| | | | | |

-CL-CURRENT: <u>424/185.1</u>; <u>514/397</u>, <u>514/422</u>, <u>530/409</u>, <u>548/314.7</u>, <u>548/517</u>

| Fi | ıll | Title | Citation F | ront | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Drawi Desc | Image |
|---|-------------|---|--|---|---------------|----------------|------------|-----------|-----------|-------------|--|---|---|--|
| | | | | | | | | | | | | | | |
| *************************************** | *********** | *************************************** | mara manananan mananan | *************************************** | ····· | | | | | | ·//··································· | *************************************** | *************************************** | ************************************** |
| Г | 2 | . D | ocument II | D: US | 3 2004 | 0082646 A | \ 1 | | | | | | | |

L4: Entry 2 of 30

File: PGPB

Apr 29, 2004

PUB-DOCUMENT-NUMBER: 20040082646

PUB-FILING-TYPE: new

CUMENT-IDENTIFIER: US 20040082646 A1

TLE: Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases

BLICATION-DATE: April 29, 2004

VENTOR-INFORMATION:

| CITY | STATE | COUNTRY | RULE-47 |
|-----------|-----------------------------------|-----------------------------------|--------------------------------------|
| Bagsvaerd | | DK | |
| Stenlose | , | DK | |
| Horsholm | | DK | |
| Hvidovre | | DK | |
| | Bagsvaerd Stenlose Horsholm | Bagsvaerd Stenlose Horsholm | Bagsvaerd DK Stenlose DK Horsholm DK |

Kristiansen, Marit

Soborg

DK

S-CL-CURRENT: 514/423; 514/424, 514/426

| Fu | | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KMC | Draw. Deśc | Image |
|--|----|-------|---|--|---------|----------------|------|-----------|-----------|-------------|--------|---|------------|-------|
| | | | | | | | | | | | | | | |
| ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | | ····· | *************************************** | ······································ | | | | | | | | *************************************** | | |
| | 3. | Doc | ument | ID: U | JS 2004 | 0082641 A | 1 | | | | | | | |

L4: Entry 3 of 30

File: PGPB

Apr 29, 2004

GPUB-DOCUMENT-NUMBER: 20040082641

GPUB-FILING-TYPE: new

OCUMENT-IDENTIFIER: US 20040082641 A1

ITLE: Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases

UBLICATION-DATE: April 29, 2004

NVENTOR - INFORMATION:

| CITY | STATE | COUNTRY | RULE-47 |
|-----------|---|---|--|
| Bagsvaerd | | DK | |
| Stenlose | | DK | |
| Horsholm | • | DK | |
| Hvidovre | | DK | |
| Soborg | | DK | |
| | Bagsvaerd Stenlose Horsholm Hvidovre | Bagsvaerd Stenlose Horsholm Hvidovre | Bagsvaerd DK Stenlose DK Horsholm DK Hvidovre DK |

S-CL-CURRENT: 514/408; 514/423, 514/424, 514/426

| Full | Titi | e Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWC | Drawi Desc | Image |
|------|------|------------|--------|---------|----------------|------|-----------|-----------|-------------|--------|--|------------|-------|
| | | | | | | | | | | | | | |
| | | | | | | | | | | | ************************************** | | |
| | I. I | ocument) | :ID: I | JS 2004 | 0009908 A | 1 | | | | | | | |

L4: Entry 4 of 30

File: PGPB

Jan 15, 2004

RULE-47

COUNTRY

GPUB-DOCUMENT-NUMBER: 20040009908

GPUB-FILING-TYPE: new

OCUMENT-IDENTIFIER: US 20040009908 A1

ITLE: Methods for treating or preventing ischemic injury

UBLICATION-DATE: January 15, 2004

NVENTOR-INFORMATION:

Stamler, Jonathan S.

JAME CITY STATE

Chapel Hill NC US

S-CL-CURRENT: 514/12

| | | | | | | | - | | | | | |
|-------|----------|-------|--------|----------------|------|-----------|-----------|-------------|--------|-------|-----------|---------|
| Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claime | kanar | Draw Desc | lmana l |

5. Document ID: US 20040006088 A1

L4: Entry 5 of 30

File: PGPB

Jan 8, 2004

PGPUB-DOCUMENT-NUMBER: 20040006088

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040006088 A1

TITLE: Substituted N-(indole-2-carbonyl) -amides and derivatives as glycogen phosphorylase

inhibitors

PUBLICATION-DATE: January 8, 2004

INVENTOR - INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|---------------------|-------------|-------|---------|---------|
| Hoover, Dennis J. | Stonington | CT | US | |
| Hulin, Bernard | Essex | CT | US | |
| Martin, William H. | Essex | CT | US | |
| Treadway, Judith L. | Gales Ferry | CT | US | |

US-CL-CURRENT: 514/252.06; 514/255.05, 514/256, 514/339, 514/365, 514/374, 514/397, 514/406, 514/414, 544/238, 544/333, 544/405, 546/277.4, 548/181, 548/206, 548/215, 548/240, 548/312.1, 548/364.7, 548/465

| Full Title Citation Front Review Classification Da | ite Referer | nce Sequences | Attachments | Claims | KWIC | Drawi Desc | Image |
|--|-------------|---|-------------|--------|-------|------------|-------|
| | | | | | | | |
| | | an saine shikisa ahali ahal | | | ····· | | |
| ☐ 6. Document ID: US 20040002454 A1 | | | | | | | |
| L4: Entry 6 of 30 | | File: PGPB | | | | Jan 1, | 2004 |

PGPUB-DOCUMENT-NUMBER: 20040002454

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040002454 A1

TITLE: Treatment of acute coronary syndrome with GLP-1

PUBLICATION-DATE: January 1, 2004

INVENTOR-INFORMATION:

NAME CITY COUNTRY STATE RULE-47

Coolidge, Thomas R. Falls Village CT US

Ehlers, Mario Lincoln NE US

US-CL-CURRENT: <u>514/12</u>

| Fu | 111 | Title Citation From | nt Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Drawi Desc | Image |
|------------|-----|---------------------|-----------------|--|------|-----------|-----------|--|--|------|------------|--|
| | | | | | | | | | | , | | |
| managarana | | | www.commons.com | CONTROL FOR PORTER CONTROL FOR | | | | The state of the s | CO 1000000000000000000000000000000000000 | | v | MALLON MARKET STATE OF THE STAT |
| | 7. | Document ID: | US 2003 | 0199553 A | .1 | | | | | | | |

L4: Entry 7 of 30

File: PGPB Oct 23, 2003 PGPUB-DOCUMENT-NUMBER: 20030199553

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030199553 A1

TITLE: Antidiabetic agents

PUBLICATION-DATE: October 23, 2003

INVENTOR-INFORMATION:

NAME

CITY

STATE

COUNTRY

RULE-47

Gammill, Ronald B.

East Lyme

CT

US

US-CL-CURRENT: <u>514/323; 514/414</u>, <u>546/201</u>, <u>548/454</u>

| F۱ | 1 | Title Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWC | Draw, Desc | Image |
|----|--------------|----------------|--|--------|----------------|------|-----------|-----------|-------------|--------|-----|--|-------|
| | | | | | | | | | | | | | • |
| | anne motorno | | Hereka di karanda kara | | ···· | | | | | | | ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ | |
| П | 8. | Document l | D: U | S 2003 | 0195361 A | 1 | | | | | | | |

L4: Entry 8 of 30

File: PGPB

Oct 16, 2003

PGPUB-DOCUMENT-NUMBER: 20030195361

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030195361 A1

TITLE: Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors

PUBLICATION-DATE: October 16, 2003

INVENTOR-INFORMATION:

NAME

CITY

STATE

COUNTRY

RULE-47

Du Bois, Daisy Joe

Palo Alto

CA

US

US-CL-CURRENT: <u>548/153</u>; <u>548/218</u>, <u>548/303.1</u>, <u>548/453</u>

| Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Desc Imag | ge |
|--------------|-------|----------|-------|--------|----------------|------|---|-----------|-------------|---|------------------|-------------------|----|
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| ************ | | | | | | ~~~~ | *************************************** | | | *************************************** | **************** | | |

9. Document ID: US 20030096827 A1

L4: Entry 9 of 30

File: PGPB

May 22, 2003

PGPUB-DOCUMENT-NUMBER: 20030096827

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030096827 A1

TITLE: Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same

PUBLICATION-DATE: May 22, 2003

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|-----------------------|-----------------|-------|---------|---------|
| Yu, Guixue | Lawrenceville | NJ | US | |
| Macor, John | Guilford | CT | US | |
| Herpin, Timothy | Princeton | NJ | US | |
| Lawrence, R. Michael | Yardley | PA | US | |
| Morton, George C. | Collegeville | PA | US | |
| Ruel, Rejean | Saint-Lambert | CT | CA | |
| Poindexter, Graham S. | Old Saybrook | | US | |
| Ruediger, Edward H. | Greenfield Park | | CA | |
| Thibault, Carl | Mascouche | | CA | |
| | | | | |

JS-CL-CURRENT: <u>514/255.01</u>; <u>514/330</u>, <u>514/616</u>, <u>544/386</u>, <u>546/207</u>, <u>546/226</u>, <u>558/430</u>, <u>558/445</u>, <u>564/152</u>

| Full | Tit | e Citation Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWC | Draw. Desc | Image |
|------|-----|------------------|--------|----------------|------------|-----------|-----------|-------------|--------|-----|------------|-------|
| | | | | | | | | | | | | |
| | 10. | Document ID: | US 200 |)30092732 A | A 1 | | | | | | | |

L4: Entry 10 of 30

File: PGPB

May 15, 2003

PGPUB-DOCUMENT-NUMBER: 20030092732

PGPUB-FILING-TYPE: new

OCUMENT-IDENTIFIER: US 20030092732 A1

TITLE: Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same

PUBLICATION-DATE: May 15, 2003

NVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|-----------------------|-----------------|-------|---------|---------|
| Yu, Guixue | Lawrenceville | NJ | US | |
| Macor, John | Guilford | CT | US | |
| Herpin, Timothy | Princeton | NJ | US | |
| Lawrence, R. Michael | Yardley | PA | US | |
| Morton, George C. | Collegeville | PA | US | |
| Ruel, Rejean | Saint-Lambert | CT | CA | |
| Poindexter, Graham S. | Old Saybrook | | US | |
| Ruediger, Edward H. | Greenfield Park | | CA | |
| Thibault, Carl | Mascouche | | CA | |
| | | | | |

JS-CL-CURRENT: <u>514/326;</u> <u>514/330</u>, <u>546/207</u>, <u>546/226</u>

| Full Title Citation | Front Review Classification D | ate Reference Sequences | Attachments Claims KW | MC Drawi Desc Image |
|---------------------|-------------------------------|-------------------------|-----------------------|-------------------------|
| | | | | |

☐ 11. Document ID: US 20030073626 A1

L4: Entry 11 of 30

File: PGPB

Apr 17, 2003

GPUB-DOCUMENT-NUMBER: 20030073626

GPUB-FILING-TYPE: new

OCUMENT-IDENTIFIER: US 20030073626 A1

ITLE: Compositions and methods for treating peripheral vascular disease

JBLICATION-DATE: April 17, 2003

IVENTOR-INFORMATION:

AME

CITY

STATE

COUNTRY

RULE-47

athaway, David R.

Lincoln

NE

US

oolidge, Thomas R.

Falls Village

CT

US

S-CL-CURRENT: <u>514/12</u>; <u>424/722</u>, <u>424/94.4</u>, <u>514/18</u>, <u>514/23</u>, <u>514/419</u>, <u>514/458</u>

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KWC Draw Desc Image

☐ 12. Document ID: US 20020183369 A1

L4: Entry 12 of 30

File: PGPB

Dec 5, 2002

GPUB-DOCUMENT-NUMBER: 20020183369

GPUB-FILING-TYPE: new

OCUMENT-IDENTIFIER: US 20020183369 A1

ITLE: Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors

JBLICATION-DATE: December 5, 2002

VVENTOR-INFORMATION:

AME

CITY

STATE

COUNTRY

RULE-47

u Bois, Daisy Joe

Palo Alto

CA

US

S-CL-CURRENT: <u>514/367</u>; <u>514/375</u>, <u>514/393</u>, <u>514/412</u>, <u>548/153</u>, <u>548/217</u>, 548/303.1, 548/453

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KMC Draw Desc Image

☐ 13. Document ID: US 20020147131 A1

L4: Entry 13 of 30

File: PGPB

Oct 10, 2002

GPUB-DOCUMENT-NUMBER: 20020147131

GPUB-FILING-TYPE: new

OCUMENT-IDENTIFIER: US 20020147131 A1

ITLE: Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused

keletal muscle tissue

JBLICATION-DATE: October 10, 2002

NVENTOR-INFORMATION:

AME

CITY

STATE

COUNTRY

RULE-47

oolidge, Thomas R.

Falls Village

CT

US

hlers, Mario R.W.

Lincoln

NE

US

S-CL-CURRENT: <u>514/2</u>; <u>530/308</u>

| Full | Titl | e Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image |
|------|-------------|------------|---------|--------|----------------|------------|-----------|-----------|-------------|--------|--|--------------------------------|-------|
| | | | | | | | | | | | | | |
| | | | | | | | | | | ···· | ////////////////////////////////////// | ****************************** | |
| | 14. | Documer | nt ID: | US 200 | 20107206 | A 1 | | | | | | | |

L4: Entry 14 of 30

File: PGPB

Aug 8, 2002

GPUB-DOCUMENT-NUMBER: 20020107206

GPUB-FILING-TYPE: new

OCUMENT-IDENTIFIER: US 20020107206 A1

ITLE: Treatment of acute coronary syndrome with GLP-1

UBLICATION-DATE: August 8, 2002

NVENTOR-INFORMATION:

IAME

CITY

STATE

COUNTRY

RULE-47

Coolidge, Thomas R.

Falls Village

CT

US

Chlers, Mario

Lincoln

NE

US

S-CL-CURRENT: 514/21

| Full | Titi | e Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KMIC | Draw Desc | lmage |
|------|------|------------|-------|----------|----------------|------|-----------|-----------|-------------|--|------|-----------|-------|
| | | | | | | | | | | | | | |
| | | | | | ····· | | Witness | | | and the second s | | | |
| _ 1 | _ | Ъ | . 115 | T TO 200 | 20055460 | A 1 | | | | | | | |
| 1 1 | Э. | Documen | t ID: | US 200 | 20055460 | AI | | | | | | | |

L4: Entry 15 of 30

File: PGPB

May 9, 2002

GPUB-DOCUMENT-NUMBER: 20020055460

GPUB-FILING-TYPE: new

OCUMENT-IDENTIFIER: US 20020055460 A1

ITLE: Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused issue

IAME

UBLICATION-DATE: May 9, 2002

NVENTOR-INFORMATION:

CITY

STATE

COUNTRY

RULE-47

oolidge, Thomas R.

Falls Village

CT

US

hlers, Mario R.W.

Lincoln

NE

US

S-CL-CURRENT: <u>514/2;</u> <u>514/23</u>, <u>514/53</u>

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KMC Draw Desc Image

☐ 16. Document ID: US 20020028810 A1

L4: Entry 16 of 30

File: PGPB

Mar 7, 2002

PUB-DOCUMENT-NUMBER: 20020028810

SPUB-FILING-TYPE: new

CUMENT-IDENTIFIER: US 20020028810 A1

TLE: Substituted N-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase

hibitors

JBLICATION-DATE: March 7, 2002

IVENTOR-INFORMATION:

COUNTRY CITY STATE RULE-47 \mathtt{AME} oover, Dennis J. Stonington CTUS US ulin, Bernard Essex CTartin, William H. Essex CTUS readway, Judith L. CTUS Gales Ferry

S-CL-CURRENT: 514/241; 514/252.06, 514/255.06, 514/256, 514/339, 514/365, 514/374, 514/378, <u>14/397, 514/406, 514/414</u>

| Fu | II Ti | le Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWC | Drawl Desc | Image |
|---|-------|-------------|-------|--------|---|------|-----------|-----------|-------------|----------------------|--------------------|------------|--------------------|
| | | | | | | | | | | | | | |
| *************************************** | | | | | ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ | | | | | sumeronanaeonaaan sa | 2077111111121297AC | | engermanne engelee |
| П | 17. | Document | ID: | US 671 | 3487 B2 | | | | | | | | |

L4: Entry 17 of 30

File: USPT

Mar 30, 2004

S-PAT-NO: 6713487

CUMENT-IDENTIFIER: US 6713487 B2

ITLE: Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions omprising same

ATE-ISSUED: March 30, 2004

IVENTOR-INFORMATION:

| | | 4 | | | |
|----------------------|-----------------|-------|-----|------|---------|
| AME | CITY | STATE | ZIP | CODE | COUNTRY |
| u; Guixue | Lawrenceville | NJ | | | |
| acor; John | Guilford | CT | | | |
| erpin; Timothy | Princeton | NJ | | | |
| awrence; R. Michael | Yardley | PA | | | |
| orton; George C. | Collegeville | PA | | | |
| uel; Rejean | Saint-Lambert | | | | CA |
| oindexter; Graham S. | Old Saybrook | CT | | | |
| uediger; Edward H. | Greenfield Park | | | | CA |
| hibault; Carl | Mascouche | | | | CA |
| | | | | | |

| ☐ 18. Document ID: | US 6706892 B1 | | |
|--|---|--|---------------------------------|
| L4: Entry 18 of 30 | F | ile: USPT | Mar 16, 2004 |
| PAT-NO: 6706892 CUMENT-IDENTIFIER: US 67 | 706892 B1 | | |
| LE: Pulmonary delivery | for bioconjugation | | |
| E-ISSUED: March 16, 200 |)4 | | |
| ENTOR-INFORMATION: | | | |
| 1E | CITY | STATE ZIP CO | DDE COUNTRY |
| in; Alan M. | Moraga | CA | |
| ser; Angelica | Montreal | - | CA |
| itaille; Martin | Terrasse-Vaudreuil | | CA |
| ner; Peter G. | Los Altos Hills | CA | |
| don; Dominique P. | Outremont | | CA |
| CL-CURRENT: <u>548</u> / <u>548</u> ; <u>42</u> / <u>93</u> , <u>548</u> / <u>520</u> | $\frac{24}{45}$, $\frac{424}{489}$, $\frac{424}{78.17}$, | <u>424/78.37</u> , <u>544/269</u> , <u>5</u> | <u>44/372, 546/208,</u> |
| Full Title Citation Front | Review Classification Date Reference | e rannanga Artennene Clai | ims KWMC Draw. Desc Image |
| | | | |

-PAT-NO: 6706689

CUMENT-IDENTIFIER: US 6706689 B2

TLE: Treatment of acute coronary syndrome with $\underline{\text{GLP-1}}$

TE-ISSUED: March 16, 2004

VENTOR-INFORMATION:

ME CITY

Falls Village

STATE ZIP CODE COUNTRY

oolidge; Thomas R.

CT

lers; Mario

Lincoln

NE

-CL-CURRENT: 514/12; 514/2

☐ 20. Document ID: US 6649634 B2

L4: Entry 20 of 30

File: USPT

Nov 18, 2003

S-PAT-NO: 6649634

OCUMENT-IDENTIFIER: US 6649634 B2

ITLE: Substituted N-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase

nhibitors

ATE-ISSUED: November 18, 2003

NVENTOR-INFORMATIÒN:

AME

CITY

STATE

ZIP CODE

COUNTRY

oover; Dennis J.

Stonington

CT

ulin; Bernard

Essex Essex CTCT

artin; William H. readway; Judith L.

Gales Ferry

CT

G-CL-CURRENT: <u>514/339</u>; <u>546/277.4</u>, <u>546/279.1</u>

| Full 1 | itle Citation | Front | Review | Classification | Date | Reference | 10.00 | 10.155191-11 | Claims | KWIC | Draw Desc | Image | |
|-----------|---------------|---|---------|----------------|------|-----------|---------|--------------|--------|---|-----------|-------|--|
| | | | | | | | | | | _ | | | |
| TT | | *************************************** | • | | ** | | | | | *************************************** | | | |
| C 21 | D | in i | 10 657 | ((52 D2 | | | | | | | | | |
| J. 21. | Documen | tid: (| 72 62 1 | 0033 B2 | | | | | | | | | |
| L4: Entry | 7 21 of 30 | | | | | Fil | e: USPT | | | Ċ | Jun 10, | 2003 | |

S-PAT-NO: 6576653

CUMENT-IDENTIFIER: US 6576653 B2

ITLE: Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors

ATE-ISSUED: June 10, 2003

VENTOR-INFORMATION:

AME

CITY

STATE

ZIP CODE

COUNTRY

Aug 6, 2002

u Bois; Daisy Joe

Palo Alto

CA

3-CL-CURRENT: 514/414; 514/237.2, 514/318, 544/111, 546/198, 548/406, 548/453

| Full Title Citation Front Review Classification | Date Reference Sergious & State Interns (| Claims KMC Draw Desc Image |
|---|---|----------------------------|
| | | |
| ☐ 22. Document ID: US 6429197 B1 | | 1 |
| 4: Entry 22 of 30 | File: USPT | Aug 6, 2002 |

-PAT-NO: 6429197

CUMENT-IDENTIFIER: US 6429197 B1

TLE: Metabolic intervention with GLP-1 or its biologically active analogues to improve the nction of the ischemic and reperfused brain

ATE-ISSUED: August 6, 2002

NVENTOR-INFORMATION:

JAME CITY

STATE

COUNTRY

Coolidge; Thomas R.

Falls Village

CT

Ehlers; Mario R. W.

Lincoln

NE

IS-CL-CURRENT: <u>514/21</u>; <u>424/185.1</u>, <u>514/12</u>, <u>514/2</u>, <u>514/3</u>, <u>530/3</u>03, 530/308, 530/324, 530/350

| Fı | 111 | Title | Citation | Front | Review | Classification | Date | Reference | 77 | 7 25 | G | laims | KWC | Draww Desç | Image |
|----|-----|-------|----------|-----------------------------|---------|----------------|------|-----------|----|------|---|-------|-----|------------|-------------|
| | ~~~ | | |)2)20.20.20.20.2 | | | | | | | | ·· | | | ··········· |
| П | 22 | | ocumen | t ID+ I | US 6399 | 9601 B1 | | | | | | | | | |

L4: Entry 23 of 30

File: USPT

Jun 4, 2002

S-PAT-NO: 6399601

OCUMENT-IDENTIFIER: US 6399601 B1

ITLE: Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors

ATE-ISSUED: June 4, 2002

NVENTOR-INFORMATION:

JAME

CITY

STATE

ZIP CODE

ZIP CODE

COUNTRY

Du Bois; Daisy Joe

Palo Alto

CA

S-CL-CURRENT: 514/233.8; 206/566, 514/321, 514/365, 514/419, 544/143, 546/198, 548/181,

48/453 Full Title Citation Front Review Classification Date Reference

| | | | |
|------|--------------|---------------|--|
| 24. | Document ID: | US 6297269 B1 | |

L4: Entry 24 of 30

File: USPT

Oct 2, 2001

S-PAT-NO: 6297269

OCUMENT-IDENTIFIER: US 6297269 B1

ITLE: Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase

nhibitors

ATE-ISSUED: October 2, 2001

NVENTOR-INFORMATION:

JAME CITY STATE ZIP CODE COUNTRY

Hulin; Bernard Essex CTHoover; Dennis J. Stonington CTTreadway; Judith L. Gales Ferry CT

Martin; William H.

Essex

CT

-CL-CURRENT: <u>514/414</u>; <u>548/491</u>, <u>548/492</u>

| Fu | ll Ti | tle Citation | Front | Review | Classification | Date | Reference | | Claims | KWIC | Drawi Desc | Image |
|---|-------|--------------|-------|--------|----------------|------|-----------|--|--------|------|--|-------|
| | | | | | | | | | | | | |
| *************************************** | | | | | | | | | | | ************************************** | |
| | 25. | Documen | t ID: | US 628 | 4725 B1 | | | | | | | |

L4: Entry 25 of 30

File: USPT

Sep 4, 2001

-PAT-NO: 6284725

CUMENT-IDENTIFIER: US 6284725 B1

TLE: Metabolic intervention with $\underline{\text{GLP-1}}$ to improve the function of ischemic and reperfused ssue

TE-ISSUED: September 4, 2001

VENTOR-INFORMATION:

AME

CITY

STATE

ZIP CODE C

COUNTRY

polidge; Thomas R.

Falls Village

CT

nlers; Mario R. W.

Lincoln

NE

-CL-CURRENT: 514/2; 424/185.1, 514/12, 530/300, 530/324

| Full 1 | itle Citation Front Review Classific | ation Date Reference | | Claims KWC | Draw. Desc Image |
|-------------|--|----------------------|--|------------|--------------------|
| | | | | | |
| | | | ······································ | | |
| □ 26. | Document ID: US 6277877 F | 31 | | | |

L4: Entry 26 of 30

File: USPT

Aug 21, 2001

-PAT-NO: 6277877

CUMENT-IDENTIFIER: US 6277877 B1

TLE: Substituted n-(indole-2-carbonyl)glycinamides and derivates as glycogen phosphorylase

TE-ISSUED: August 21, 2001

VENTOR-INFORMATION:

| AME | CITY | STATE | ZIP CODE | COUNTRY |
|--------------------|-------------|-------|----------|---------|
| pover; Dennis J. | Stonington | CT | | |
| ılin; Bernard | Essex | CT | | |
| artin; William H. | Essex | CT | | |
| nillips; Douglas | Gales Ferry | CT | ı | |
| readway; Judith L. | Gales Ferry | CT | | |
| | | | | |

-CL-CURRENT: <u>514/415</u>; <u>514/18</u>, <u>514/228.2</u>, <u>514/233.5</u>, <u>514/234.5</u>, <u>514/252.02</u>, <u>514/252.06</u>, <u>4/255.05</u>, <u>514/323</u>, <u>514/330</u>, <u>514/385</u>, <u>514/419</u>, <u>548/100</u>

☐ 27. Document ID: US 6107329 A

L4: Entry 27 of 30

File: USPT

Aug 22, 2000

-PAT-NO: 6107329

CUMENT-IDENTIFIER: US 6107329 A

TLE: Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase

hibitors

TE-ISSUED: August 22, 2000

VENTOR-INFORMATION:

ZIP CODE ME CITY STATE COUNTRY

Stonington CTover; Dennis J.

lin; Bernard Essex СT

Essex CTartin; William H.

CTnillips; Douglas Gales Ferry Gales Ferry CT

readway; Judith L.

-CL-CURRENT: 514/415; 514/18, 514/235.2, 514/323, 514/330, 514/385, 514/419, 548/100

| Ful | T | tle Citation | Front | Review | Classification | Date | Reference | | Claims | KWIC | Drawi Desc | lmage |
|------|-----|--------------|--------|--------|----------------|------|---|---|--------|------|------------|-------|
| | | | | | | | | | | | | |
| | | | | | | | *************************************** | | | | | |
| | | | | | | | | | | | | |
| | 28. | Documen | it ID: | US 599 | 8463 A | | | • | | | | |

L4: Entry 28 of 30

File: USPT

Dec 7, 1999

-PAT-NO: 5998463

CUMENT-IDENTIFIER: US 5998463 A

See image for Certificate of Correction **

TLE: Glycogen phosphorylase inhibitors

TE-ISSUED: December 7, 1999

VENTOR-INFORMATION:

ME

CITY

STATE

ZIP CODE

COUNTRY

ılin; Bernard

Essex

CT

arges; Reinhard

Mystic

CT

-CL-CURRENT: 514/418; 548/486

| Full | Title | e Citation | Front | Review | Classification | Date | Reference | | Claims | KWIC | Draw Desc | Image |
|------|-------|------------|--------|--------|----------------|------------|-----------|-------------|--------|---|-----------|-------|
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | *************************************** | | |
| | 29. | Documer | nt ID: | US 20 | 020055460 | A 1 | | | | | | |

L4: Entry 29 of 30

File: DWPI

May 9, 2002

DERWENT-ACC-NO: 2002-470984

DERWENT-WEEK: 200250

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Method of metabolic intervention with <u>glucagon-like peptide-1</u>, useful for improving the function of ischemic and reperfused tissue, comprises administration with a carrier

INVENTOR: COOLIDGE, T R; EHLERS, M R W

PRIORITY-DATA: 1998US-103498P (October 8, 1998), 1999US-0302596 (April 30, 1999), 2001US-0851738 (May 9, 2001)

PATENT-FAMILY:

PUB-NO US 20020055460 A1 PUB-DATE
May 9, 2002

LANGUAGE

PAGES

MAIN-IPC

008

A61K038/17

INT-CL (IPC): A61 K 31/70; A61 K 38/17

| Full Title Cit. | ation Front Re | eview Classification | Date Reference | F21016 | Claims KWMC | Draw Desc Image |
|--|--|--|----------------|--------|-------------|--|
| | | | | | | |
| ************************************** | annanan meranan merana | TENNING TO THE CONTROL OF THE CONTRO | | | | TO THE RESIDENCE OF THE PROPERTY OF THE PROPER |

30. Document ID: NZ 514609 A, WO 200066142 A2, AU 200046825 A, NO 200105298 A, EP 1187628 A2, JP 2002543145 W, CN 1376072 A, MX 2001010937 A1

L4: Entry 30 of 30

File: DWPI

Mar 26, 2004

DERWENT-ACC-NO: 2001-015911

DERWENT-WEEK: 200425

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: A method for amelioration of brain tissue injury comprises administering a composition including a compound which binds to a receptor for glucagon-like peptide-1

INVENTOR: COOLIDGE, T R; EHLERS, M R W

PRIORITY-DATA: 1999US-0303016 (April 30, 1999)

PATENT-FAMILY:

| PUB-NO | PUB-DATE | LANGUAGE | PAGES | MAIN-IPC |
|------------------|-------------------|----------|-------|------------|
| NZ 514609 A | March 26, 2004 | | 000 | A61K038/00 |
| WO 200066142 A2 | November 9, 2000 | E | 017 | A61K038/00 |
| AU 200046825 A | November 17, 2000 | | 000 | |
| NO 200105298 A | December 28, 2001 | | 000 | A61K000/00 |
| EP 1187628 A2 | March 20, 2002 | E | 000 | A61K038/26 |
| JP 2002543145 W | December 17, 2002 | | 025 | A61K045/00 |
| CN 1376072 A | October 23, 2002 | | 000 | A61K038/26 |
| MX 2001010937 A1 | June 1, 2002 | | 000 | A61K038/00 |
| | | | | |

INT-CL (IPC): A61 K 0/00; A61 K 31/7004; A61 K 38/00; A61 K 38/26; A61 K 45/00; A61 P 7/00; A61 P 9/10; A61 P 25/00; A61 K 31:7004; A61 K 38/26; A61 K 31:7004; A61 K 33:00; A61 K 38/26; A61 K 38/26; A61 K 38/26; A61 K 38:44; A61 K 38/26; A61 K 38:06

Full | Title | Citation | Front | Review | Classification | Date | Reference | Section | Atlantic | Atlantic | Claims | KMC | Draw Desc | Image |

| Clear Generate Collection Print Fwd Refs Bkwd Refs | Generate OACS |
|--|---------------|
| Term | Documents |
| GLUCAGON | 7114 |
| GLUCAGONS | 167 |
| LIKE | 2843812 |
| LIKES | 6258 |
| PEPTIDE | 144607 |
| PEPTIDES | 106440 |
| "1" | 18027084 |
| 1S | 17963 |
| GLP-1 | 1361 |
| GLP-1S | 2 |
| (((GLUCAGON SAME LIKE SAME PEPTIDE ADJ 1) OR GLP-1) AND REPERFUSION AND ISCHEMIA AND TISSUE ADJ DAMAGE).PGPB,USPT,EPAB,DWPI,TDBD. | 30 |

There are more results than shown above. Click here to view the entire set.

Previous Page Next Page FILE 'HOME' ENTERED AT 15:03:46 ON 19 OCT 2004

=> file bioscience and dissabs
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

'AND' IS NOT A VALID FILE NAME

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):bioscience dissabs

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY 0.42 SESSION 0.42

FULL ESTIMATED COST

FILE 'ADISCTI' ENTERED AT 15:05:06 ON 19 OCT 2004 COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 15:05:06 ON 19 OCT 2004 COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 15:05:06 ON 19 OCT 2004 COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 15:05:06 ON 19 OCT 2004

FILE 'ANABSTR' ENTERED AT 15:05:06 ON 19 OCT 2004 COPYRIGHT (c) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'ANTE' ENTERED AT 15:05:06 ON 19 OCT 2004 COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'AQUALINE' ENTERED AT 15:05:06 ON 19 OCT 2004 COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'AQUASCI' ENTERED AT 15:05:06 ON 19 OCT 2004 COPYRIGHT 2004 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 15:05:06 ON 19 OCT 2004 Copyright (c) 1998 The Thomson Corporation.

FILE 'BIOCOMMERCE' ENTERED AT 15:05:06 ON 19 OCT 2004 COPYRIGHT (C) 2004 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved

FILE 'BIOENG' ENTERED AT 15:05:06 ON 19 OCT 2004 COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'BIOSIS' ENTERED AT 15:05:06 ON 19 OCT 2004 Copyright (c) 2004 The Thomson Corporation.

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 15:05:06 ON 19 OCT 2004 COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'BIOTECHNO' ENTERED AT 15:05:06 ON 19 OCT 2004 COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 15:05:06 ON 19 OCT 2004 COPYRIGHT (C) 2004 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 15:05:06 ON 19 OCT 2004

FILE 'CAPLUS' ENTERED AT 15:05:06 ON 19 OCT 2004 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 15:05:06 ON 19 OCT 2004 COPYRIGHT (c) 2004 DECHEMA eV

FILE 'CEN' ENTERED AT 15:05:06 ON 19 OCT 2004 COPYRIGHT (C) 2001 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 15:05:06 ON 19 OCT 2004 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 15:05:06 ON 19 OCT 2004 COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 15:05:06 ON 19 OCT 2004 COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'CROPU' ENTERED AT 15:05:06 ON 19 OCT 2004 COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DDFB' ENTERED AT 15:05:06 ON 19 OCT 2004 COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 15:05:06 ON 19 OCT 2004 COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DISSABS' ENTERED AT 15:05:06 ON 19 OCT 2004 COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'DRUGB' ENTERED AT 15:05:06 ON 19 OCT 2004 COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DRUGMONOG2' ENTERED AT 15:05:06 ON 19 OCT 2004 COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 15:05:06 ON 19 OCT 2004 COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'EMBAL' ENTERED AT 15:05:06 ON 19 OCT 2004 COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 15:05:06 ON 19 OCT 2004 COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 15:05:06 ON 19 OCT 2004 COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 15:05:06 ON 19 OCT 2004

FILE 'FOMAD' ENTERED AT 15:05:06 ON 19 OCT 2004 COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 15:05:06 ON 19 OCT 2004 COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 15:05:06 ON 19 OCT 2004 COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 15:05:06 ON 19 OCT 2004 COPYRIGHT (C) 2004 International Food Information Service

FILE 'GENBANK' ENTERED AT 15:05:06 ON 19 OCT 2004

FILE 'HEALSAFE' ENTERED AT 15:05:06 ON 19 OCT 2004 COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 15:05:06 ON 19 OCT 2004 COPYRIGHT (C) 2004 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSDRUGNEWS' ENTERED AT 15:05:06 ON 19 OCT 2004 COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSPRODUCT' ENTERED AT 15:05:06 ON 19 OCT 2004 COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSRESEARCH' ENTERED AT 15:05:06 ON 19 OCT 2004 COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 15:05:06 ON 19 OCT 2004 COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 15:05:06 ON 19 OCT 2004 COPYRIGHT (C) 2004 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 15:05:06 ON 19 OCT 2004 COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 15:05:06 ON 19 OCT 2004 COPYRIGHT (c) 2004 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 15:05:06 ON 19 OCT 2004

FILE 'NIOSHTIC' ENTERED AT 15:05:06 ON 19 OCT 2004 COPYRIGHT (C) 2004 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 15:05:06 ON 19 OCT 2004 Compiled and distributed by the NTIS, U.S. Department of Commerce. It contains copyrighted material. All rights reserved. (2004)

FILE 'NUTRACEUT' ENTERED AT 15:05:06 ON 19 OCT 2004 Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 15:05:06 ON 19 OCT 2004 COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 15:05:06 ON 19 OCT 2004
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 15:05:06 ON 19 OCT 2004 COPYRIGHT (C) 2004 WIPO

FILE 'PHAR' ENTERED AT 15:05:06 ON 19 OCT 2004 COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 15:05:06 ON 19 OCT 2004 Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 15:05:06 ON 19 OCT 2004 COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

```
FILE 'PHIN' ENTERED AT 15:05:06 ON 19 OCT 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)
FILE 'PROMT' ENTERED AT 15:05:06 ON 19 OCT 2004
COPYRIGHT (C) 2004 Gale Group. All rights reserved.
FILE 'PROUSDDR' ENTERED AT 15:05:06 ON 19 OCT 2004
COPYRIGHT (C) 2004 Prous Science
FILE 'PS' ENTERED AT 15:05:06 ON 19 OCT 2004
COPYRIGHT (C) 2004 Thieme on STN
FILE 'RDISCLOSURE' ENTERED AT 15:05:06 ON 19 OCT 2004
COPYRIGHT (C) 2004 Kenneth Mason Publications Ltd.
FILE 'SCISEARCH' ENTERED AT 15:05:06 ON 19 OCT 2004
Copyright (c) 2004 The Thomson Corporation.
FILE 'SYNTHLINE' ENTERED AT 15:05:06 ON 19 OCT 2004
COPYRIGHT (C) 2004 Prous Science
FILE 'TOXCENTER' ENTERED AT 15:05:06 ON 19 OCT 2004
COPYRIGHT (C) 2004 ACS
FILE 'USPATFULL' ENTERED AT 15:05:06 ON 19 OCT 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'USPAT2' ENTERED AT 15:05:06 ON 19 OCT 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'VETB' ENTERED AT 15:05:06 ON 19 OCT 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION
FILE 'VETU' ENTERED AT 15:05:06 ON 19 OCT 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION
FILE 'WATER' ENTERED AT 15:05:06 ON 19 OCT 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)
FILE 'WPIDS' ENTERED AT 15:05:06 ON 19 OCT 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION
FILE 'WPIFV' ENTERED AT 15:05:06 ON 19 OCT 2004
COPYRIGHT (C) 2004 THOMSON DERWENT
FILE 'WPINDEX' ACCESS NOT AUTHORIZED
=> s ((glucagon (s) like (s) peptide (w) 1) or GLP-1) and reperfusion and ischemia and
tissue (w) damage
             0 FILE ADISCTI
L1
L2
             0 FILE ADISINSIGHT
             O FILE ADISNEWS
L3
1.4
             0 FILE AGRICOLA
             0 FILE ANABSTR
L5
             O FILE ANTE
L6
L7
             0 FILE AQUALINE
L8
             0 FILE AQUASCI
Ь9
             0 FILE BIOBUSINESS
L10
             0 FILE BIOCOMMERCE
L11
             0 FILE BIOENG
L12
             0 FILE BIOSIS
L13
             0 FILE BIOTECHDS
L14
             0 FILE BIOTECHNO
             0 FILE CABA
L15
             0 FILE CANCERLIT
L16
L17
             0 FILE CAPLUS
```

```
0 FILE CEABA-VTB
            0 FILE CEN
L19
            0 FILE CIN
L20
            0 FILE CONFSCI
L21
            0 FILE CROPB
L22
            0 FILE CROPU
L23
            0 FILE DDFB
L24
            0 FILE DGENE
L25
            0 FILE DISSABS
L26
            0 FILE DRUGB
L27
            0 FILE DRUGMONOG2
L28
            0 FILE DRUGU
L29
            0 FILE EMBAL
L30
            0 FILE EMBASE
L31
            0 FILE ESBIOBASE
L32
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'GLUCAGON (S) LIKE'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'LIKE (S) PEPTIDE'
            0 FILE FEDRIP
L34
            0 FILE FOMAD
            0 FILE FOREGE
            0 FILE FROSTI
L36
            0 FILE FSTA
L37
            0 FILE GENBANK
L38
L39
            0 FILE HEALSAFE
L40
            3 FILE IFIPAT
L41
            0 FILE IMSDRUGNEWS
           0 FILE IMSPRODUCT
L43
           0 FILE IMSRESEARCH
L44
           0 FILE JICST-EPLUS
           0 FILE KOSMET
L45
           0 FILE LIFESCI
L46
           0 FILE MEDICONF
L47
           0 FILE MEDLINE
L48
L49
           0 FILE NIOSHTIC
L50
           0 FILE NTIS
L51
            0 FILE NUTRACEUT
L52
            0 FILE OCEAN
L53
            0 FILE PASCAL
L54
            0 FILE PCTGEN
L55
            0 FILE PHAR
L56
            0 FILE PHARMAML
            0 FILE PHIC
L57
L58
            0 FILE PHIN
L59
            0 FILE PROMT
L60
            0 FILE PROUSDDR
L61
            0 FILE PS
L62
            0 FILE RDISCLOSURE
L63
           0 FILE SCISEARCH
L64
            0 FILE SYNTHLINE
            0 FILE TOXCENTER
L65
           24 FILE USPATFULL
L66
L67
           4 FILE USPAT2
L68
            0 FILE VETB
L69
            0 FILE VETU
L70
            0 FILE WATER
L71
            4 FILE WPIDS
            O FILE WPIFV
TOTAL FOR ALL FILES
```

35 ((GLUCAGON (S) LIKE (S) PEPTIDE (W) 1) OR GLP-1) AND REPERFUSION

AND ISCHEMIA AND TISSUE (W) DAMAGE

DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE,

=> dup rem 173

DRUGMONOG2, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, IMSRESEARCH, KOSMET,
MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L73
L74 27 DUP REM L73 (8 DUPLICATES REMOVED)

=> d 174 ibib abs

L74 ANSWER 1 OF 27 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 1

AN 10502705 IFIPAT; IFIUDB; IFICDB

TITLE: METHODS FOR TREATING OR PREVENTING ISCHEMIC INJURY

INVENTOR(S): Stamler; Jonathan S., Chapel Hill, NC, US

PATENT ASSIGNEE(S): Unassigned

AGENT: MINTZ, LEVIN, COHN, FERRIS, GLOVSKY and POPEO, P.C.,

One Financial Center, Boston, MA, 02111, US

| NUMBER | | | DATE |
|--------|---------------|-----|----------|
| , | | | |
| TON. | 110 200400000 | 7\1 | 20040115 |

 PATENT INFORMATION:
 US 2004009908
 A1 20040115

 APPLICATION INFORMATION:
 US 2002-192448
 20020710

 FAMILY INFORMATION:
 US 2004009908
 20040115

DOCUMENT TYPE: Utility

Patent Application - First Publication

FILE SEGMENT: CHEMICAL APPLICATION

OTHER SOURCE: CA 140:92570

NUMBER OF CLAIMS: 73 4 Figure(s).

DESCRIPTION OF FIGURES:

FIG. 1 depicts the protection of cardiac contractility when erythropoietin (EPO) is administered 5 minutes after suture ligation of the large branch of the left circumflex artery (LCx). MI only, LCx ligation alone; EPO, 5000 U/kg of EPO administered following LCx ligation. Basal contractility, at rest; Iso-Low, Isoproterenol 0.033 mu g/kg/min; Iso-High, Isoproterenol 0.1 mu g/kg/min.

FIG. 2 depicts the protection of cardiac contractility when erythropoietin (EPO) is administered 24 hours prior to suture ligation of the large branch of the left circumflex artery (LCx). MI only, LCx ligation alone; EPO, 5000 U/kg of EPO administered 24 hours prior to LCx ligation. Basal contractility, at rest; Iso-Low, Isoproterenol 0.033 mu g/kg/min; Iso-High, Isoproterenol 0.1 mu g/kg/min.

FIG. 3 depicts a comparison of the hematocrit data from animals receiving systemic normal saline (Control) versus Erythropoietin (EPO 5,000 U/kg). FIG. 4 depicts a comparison of left ventricular beta-receptor density in 3 groups: LCx ligation alone (MI Only); Administration of erythropoietin (5000 U/kg) followed by LCx ligation 24 hours later (EPO); and untreated group (Sham).

A therapeutic or prophylactic treatment method of myocardial ischemia, such as due to myocardial infarction, by administering erythropoietin, alone or in combination with other drugs, to a patient suffering from or at risk of cardiac injury, such as myocardial ischemia. The erythropoietin is administered in a concentration such that the subject's hematocrit level or production of red blood cells is not significantly affected.

CLMN 73 4 Figure(s).

ΔR

FIG. 1 depicts the protection of cardiac contractility when erythropoietin (EPO) is administered 5 minutes after suture ligation of the large branch of the left circumflex artery (LCx). MI only, LCx ligation alone; EPO, 5000 U/kg of EPO administered following LCx ligation. Basal contractility, at rest; Iso-Low, Isoproterenol 0.033 mu g/kg/min; Iso-High, Isoproterenol 0.1 mu g/kg/min.

FIG. 2 depicts the protection of cardiac contractility when erythropoietin (EPO) is administered 24 hours prior to suture ligation of the large branch of the left circumflex artery (LCx). MI only, LCx ligation alone; EPO, 5000 U/kg of EPO administered 24 hours prior to LCx ligation. Basal contractility, at rest; Iso-Low, Isoproterenol 0.033 mu g/kg/ min;

Iso-High, Isoproterenol 0.1 mu g/kg/min.

FIG. 3 depicts a comparison of the hematocrit data from animals receiving systemic normal saline (Control) versus Erythropoietin (EPO 5,000 U/kg). FIG. 4 depicts a comparison of left ventricular beta-receptor density in 3 groups: LCx ligation alone (MI Only); Administration of erythropoietin (5000 U/kg) followed by LCx ligation 24 hours later (EPO); and untreated group (Sham).

=> d 174 1-35 ibib abs

L74 ANSWER 1 OF 27 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 1

AN 10502705 IFIPAT; IFIUDB; IFICDB

METHODS FOR TREATING OR PREVENTING ISCHEMIC INJURY TITLE: INVENTOR (S):

Stamler; Jonathan S., Chapel Hill, NC, US

PATENT ASSIGNEE(S): Unassigned

AGENT: MINTZ, LEVIN, COHN, FERRIS, GLOVSKY and POPEO, P.C.,

One Financial Center, Boston, MA, 02111, US

| | NUMBER | PK | DATE |
|--------------------------|--------------------|-----|------------------|
| | | | |
| PATENT INFORMATION: | US 2004009908 | A1 | 20040115 |
| APPLICATION INFORMATION: | US 2002-192448 | | 20020710 |
| FAMILY INFORMATION: | US 2004009908 | | 20040115 |
| DOCUMENT TYPE: | Utility | | |
| | Patent Application | - F | irst Publication |

FILE SEGMENT: CHEMICAL APPLICATION

OTHER SOURCE: CA 140:92570

NUMBER OF CLAIMS: 73 4 Figure(s).

DESCRIPTION OF FIGURES:

FIG. 1 depicts the protection of cardiac contractility when erythropoietin (EPO) is administered 5 minutes after suture ligation of the large branch of the left circumflex artery (LCx) . MI only, LCx ligation alone; EPO, 5000 U/kg of EPO administered following LCx ligation. Basal contractility, at rest; Iso-Low, Isoproterenol 0.033 mu g/kg/min; Iso-High, Isoproterenol 0.1 mu g/kg/min.

FIG. 2 depicts the protection of cardiac contractility when erythropoietin (EPO) is administered 24 hours prior to suture ligation of the large branch of the left circumflex artery (LCx) . MI only, LCx ligation alone; EPO, 5000 U/kg of EPO administered 24 hours prior to LCx ligation. Basal contractility, at rest; Iso-Low, Isoproterenol 0.033 mu g/kg/ min; Iso-High, Isoproterenol 0.1 mu g/kg/min.

FIG. 3 depicts a comparison of the hematocrit data from animals receiving systemic normal saline (Control) versus Erythropoietin (EPO 5,000 U/kg). FIG. 4 depicts a comparison of left ventricular beta-receptor density in 3 groups: LCx ligation alone (MI Only); Administration of erythropoietin (5000 U/kg) followed by LCx ligation 24 hours later (EPO); and untreated group (Sham). AB

A therapeutic or prophylactic treatment method of myocardial ischemia, such as due to myocardial infarction, by administering erythropoietin, alone or in combination with other drugs, to a patient suffering from or at risk of cardiac injury, such as myocardial ischemia. The erythropoietin is administered in a concentration such that the subject's hematocrit level or production of red blood cells is not significantly affected.

CLMN 73 4 Figure(s).

FIG. 1 depicts the protection of cardiac contractility when erythropoietin (EPO) is administered 5 minutes after suture ligation of the large branch of the left circumflex artery (LCx) . MI only, LCx ligation alone; EPO, 5000 U/kg of EPO administered following LCx ligation. Basal contractility, at rest; Iso-Low, Isoproterenol 0.033 mu g/kg/min; Iso-High, Isoproterenol 0.1 mu g/kg/min.

FIG. 2 depicts the protection of cardiac contractility when erythropoietin (EPO) is administered 24 hours prior to suture ligation of the large

branch of the left circumflex artery (LCx) . MI only, LCx ligation alone; EPO, 5000 U/kg of EPO administered 24 hours prior to LCx ligation. Basal contractility, at rest; Iso-Low, Isoproterenol 0.033 mu g/kg/ min; Iso-High, Isoproterenol 0.1 mu g/kg/min.

FIG. 3 depicts a comparison of the hematocrit data from animals receiving systemic normal saline (Control) versus Erythropoietin (EPO 5,000 U/kg). FIG. 4 depicts a comparison of left ventricular beta-receptor density in 3 groups: LCx ligation alone (MI Only); Administration of erythropoietin (5000 U/kg) followed by LCx ligation 24 hours later (EPO); and untreated group (Sham).

L74 ANSWER 2 OF 27 USPATFULL on STN

ACCESSION NUMBER: 2004:202970 USPATFULL

Pulmonary delivery for bioconjugation TITLE:

Ezrin, Alan M., Moraga, CA, UNITED STATES INVENTOR(S):

> Fleser, Angelica, Montreal, CANADA Robitaille, Martin, Granby, CANADA

Milner, Peter G., Los Altos Hills, CA, UNITED STATES

Bridon, Dominique P., Ville Mont-Royal, CANADA

PATENT ASSIGNEE(S): CONJUCHEM, INC., Montreal, CANADA (U.S. corporation)

> NUMBER KIND DATE -----

PATENT INFORMATION:

US 2004156859 A1 20040812 US 2004-756774 A1 20040112 (10) APPLICATION INFO.:

Division of Ser. No. US 2000-656121, filed on 6 Sep RELATED APPLN. INFO.:

2000, GRANTED, Pat. No. US 6706892

NUMBER DATE

PRIORITY INFORMATION: US 1999-152681P 19990907 (60)

DOCUMENT TYPE: Utility FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: MORRISON & FOERSTER LLP, 425 MARKET STREET, SAN

FRANCISCO, CA, 94105-2482

EXEMPLARY CLAIM: 1 LINE COUNT:

5112

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Methods of and compositions for pulmonary delivery of therapeutic agents which are capable of forming covalent bonds with a site of interest or which have formed a covalent bond with a pulmonary solution protein are disclosed. Therapeutic agents useful in the invention include wound healing agents, antibiotics, anti-inflammatories, anti-oxidants, anti-proliferatives, immunosupressants, anti-infective and anti-cancer

agents.

PATENT INFORMATION:

APPLICATION INFO.:

NUMBER OF CLAIMS:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L74 ANSWER 3 OF 27 USPATFULL on STN

ACCESSION NUMBER: 2004:108244 USPATFULL

TITLE: Use of glycogen phosphorylase inhibitors for treatment

of cardiovascular diseases

INVENTOR(S): Rytved, Klaus Asger, Bagsvaerd, DENMARK

Dragsted, Nils, Stenlose, DENMARK

Nyborg, Niels Chresten Berg, Horsholm, DENMARK

Iversen, Lars, Hvidovre, DENMARK Kristiansen, Marit, Soborg, DENMARK

NUMBER KIND DATE US 2004082646 A1 US 2003-429626 A1 20040429

A1 20030505 (10)

NUMBER DATE

PRIORITY INFORMATION: DK 2002-1630 20021028

US 2002-422081P 20021029 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Reza Green, Esq., Novo Nordisk Pharmaceuticals, Inc.,

100 College Road West, Princeton, NJ, 08540

NUMBER OF CLAIMS: 55 EXEMPLARY CLAIM: 1

LINE COUNT: 1140

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

The present invention provides methods which may effectively be used in the treatment and prevention of early cardiac and early cardiovascular diseases, for example of ischemic origin, such as left ventricular hypertrophy, coronary artery disease, essential hypertension, acute hypertensive emergency, cardiomyopathy, heart insufficiency, exercise tolerance, chronic heart failure, arrhythmia, cardiac dysrhythmia, syncopy, arteriosclerosis, mild chronic heart failure, angina pectoris, cardiac bypass reocclusion, intermittent claudication (arteriosclerosis oblitterens), diastolic dysfunction and systolic dysfunction, as well as improving the success of heart transplantations, through administration of glycogen phosphorylase inhibitor compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L74 ANSWER 4 OF 27 USPATFULL on STN

ACCESSION NUMBER: 2004:108239 USPATFULL

TITLE: Use of glycogen phosphorylase inhibitors for treatment

of cardiovascular diseases

INVENTOR(S): Rytved, Klaus Asger, Bagsvaerd, DENMARK

Dragsted, Nils, Stenlose, DENMARK

Nyborg, Niels Chresten Berg, Horsholm, DENMARK

Iversen, Lars, Hvidovre, DENMARK Kristiansen, Marit, Soborg, DENMARK

NUMBER KIND DATE

PATENT INFORMATION: US 2004082641 A1 20040429 APPLICATION INFO.: US 2003-429625 A1 20030505 (10)

DK 2002-1630 20021028 US 2002-422081P 20021029 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Reza Green, Esq., Novo Nordisk Pharmaceuticals, Inc.,

100 College Road West, Princeton, NJ, 08540

NUMBER OF CLAIMS: 134 EXEMPLARY CLAIM: 1

LINE COUNT: 1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

The present invention provides methods of treatment and prevention of early cardiac and early cardiovascular diseases, for instance of ischemic origin, such as left ventricular hypertrophy, coronary artery disease, essential hypertension, acute hypertensive emergency, cardiomyopathy, heart insufficiency, exercise tolerance, chronic heart failure, arrhythmia, cardiac dysrhythmia, syncopy, arteriosclerosis, mild chronic heart failure, angina pectoris, cardiac bypass reocclusion, intermittent claudication (arteriosclerosis oblitterens), diastolic dysfunction and systolic dysfunction, as well as improving the success of heart transplantations, through administration of glycogen phosphorylase inhibitor compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L74 ANSWER 5 OF 27 USPATFULL on STN

ACCESSION NUMBER:

2004:7848 USPATFULL

TITLE:

Substituted N-(indole-2-carbonyl) -amides and derivatives as glycogen phosphorylase inhibitors

INVENTOR(S):

Hoover, Dennis J., Stonington, CT, UNITED STATES

Hulin, Bernard, Essex, CT, UNITED STATES

Martin, William H., Essex, CT, UNITED STATES

Treadway, Judith L., Gales Ferry, CT, UNITED STATES

PATENT ASSIGNEE(S):

NUMBER KIND DATE -----US 2004006088 A1 20040108 US 2003-464728 A1 20030617 (10)

Pfizer Inc. (U.S. corporation)

PATENT INFORMATION: APPLICATION INFO.:

RELATED APPLN. INFO.:

Division of Ser. No. US 2001-881136, filed on 14 Jun 2001, GRANTED, Pat. No. US 6649634 Division of Ser. No. US 1997-952668, filed on 2 Dec 1997, GRANTED, Pat. No.

US 6297269 A 371 of International Ser. No. WO 1995-IB443, filed on 6 Jun 1995, UNKNOWN

DOCUMENT TYPE:

Utility

FILE SEGMENT:

APPLICATION

LEGAL REPRESENTATIVE:

PFIZER INC., PATENT DEPARTMENT, MS8260-1611, EASTERN

POINT ROAD, GROTON, CT, 06340

NUMBER OF CLAIMS:

EXEMPLARY CLAIM: LINE COUNT:

4124

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

##STR1##

This invention relates to certain indole-2-carboxamides of formula (I) and the pharmaceutically acceptable salts and prodrugs thereof, wherein R.sub.6 is carboxy, (C.sub.1-C.sub.8) alkoxycarbonyl, C(0) NR.sub.8R.sub.9 or C(O)R.sub.12, useful as inhibitors of glycogen phosphorylase, methods of treating glycogen phosphorylase dependent diseases or conditions with such compounds and pharmaceutical compositions comprising such compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L74 ANSWER 6 OF 27 USPATFULL on STN

ACCESSION NUMBER:

2004:2431 USPATFULL

TITLE:

Treatment of acute coronary syndrome with GLP

INVENTOR(S):

Coolidge, Thomas R., Falls Village, CT, UNITED STATES

Ehlers, Mario, Lincoln, NE, UNITED STATES

PATENT ASSIGNEE(S):

Amylin Pharmaceuticals, Inc., San Diego, CA, UNITED

STATES, 68524 (U.S. corporation)

NUMBER KIND DATE -----US 2004002454 A1 20040101 US 2002-322839 A1 20021218

PATENT INFORMATION: APPLICATION INFO.: RELATED APPLN. INFO.:

20021218 (10) Division of Ser. No. US 2001-859804, filed on 18 May

2001, PENDING

NUMBER DATE -----

PRIORITY INFORMATION:

US 2000-205239P 20000519 (60)

DOCUMENT TYPE: FILE SEGMENT:

Utility

APPLICATION

LEGAL REPRESENTATIVE:

ARNOLD & PORTER, Attn: IP Docketing Department, Room

1126B, 555 Twelfth Street, NW, Washington, DC,

20004-1206

NUMBER OF CLAIMS:

1

EXEMPLARY CLAIM: LINE COUNT:

47 1204

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

The invention relates to methods for treating a patient suffering from acute coronary syndrome, but who is not suffering from a Q-wave myocardial infarction, comprising administration of a therapeutically effective amount of a GLP-1 molecule. The GLP-1 can be self-administered, and can be administered in one or more doses, as needed, on an intermittent or continuous basis, to optimize metabolism in cardiac tissue and to prevent cardiac damage associated with ischemia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L74 ANSWER 7 OF 27 USPATFULL on STN

ACCESSION NUMBER: 2004:66015 USPATFULL

TITLE: Pulmonary delivery for bioconjugation
INVENTOR(S): Ezrin, Alan M., Moraga, CA, United States

(S): Ezrin, Alan M., Moraga, CA, United States Fleser, Angelica, Montreal, CANADA

Robitaille, Martin, Terrasse-Vaudreuil, CANADA

Milner, Peter G., Los Altos Hills, CA, United States

Bridon, Dominique P., Outremont, CANADA

PATENT ASSIGNEE(S): Conjuchem, Inc., Montreal, CANADA (non-U.S.

corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 6706892 B1 20040316 APPLICATION INFO.: US 2000-656121 20000906 (9)

NUMBER DATE

PRIORITY INFORMATION: US 1999-152681P 19990907 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Webman, Edward J.

LEGAL REPRESENTATIVE: Morrison & Foerster LLP

NUMBER OF CLAIMS: 34

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)

LINE COUNT: 5043

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Methods of and compositions for pulmonary delivery of therapeutic agents which are capable of forming covalent bonds with a site of interest or which have formed a covalent bond with a pulmonary solution protein are disclosed. Therapeutic agents useful in the invention include wound healing agents, antibiotics, anti-inflammatories, anti-oxidants, anti-proliferatives, immunosupressants, anti-infective and anti-cancer agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L74 ANSWER 8 OF 27 WPIDS COPYRIGHT 2004 THE THOMSON CORP on STN

ACCESSION NUMBER: 2004

2004-122480 [12] WPIDS

DOC. NO. CPI:

C2004-049195

TITLE:

Use of erythropoietin for e.g. treating myocardial

ischemia, ischemia-reperfusion

injury, congestive heart failure and cardiac arrest.

DERWENT CLASS:

B04

INVENTOR(S): STAMLER, J S

PATENT ASSIGNEE(S): (STAM-I) STAMLER J S; (UYDU-N) UNIV DUKE

COUNTRY COUNT: 104

PATENT INFORMATION:

PATENT NO KIND DATE WEEK LA PO

WO 2004004664 A2 20040115 (200412) * EN 41

RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

US 2004009908 A1 20040115 (200416) AU 2003249181 A1 20040123 (200459)

APPLICATION DETAILS:

| PATENT N | O KIND | APPLICATION | DATE |
|----------|----------|-----------------|----------|
| WO 20040 | 04664 A2 | WO 2003-US21828 | 20030708 |
| US 20040 | 09908 A1 | US 2002-192448 | 20020710 |
| AU 20032 | 49181 A1 | AU 2003-249181 | 20030708 |

FILING DETAILS:

AB

| PATENT NO | KIND |] | PATENT NO |
|---------------|-------------|----|------------|
| | | | |
| AU 2003249181 | A1 Based on | WO | 2004004664 |

PRIORITY APPLN. INFO: US 2002-192448 20020710

N 2004-122480 [12] WPIDS

WO2004004664 A UPAB: 20040218

NOVELTY - Treatment of myocardial oxidative stress involves administration of erythropoietin.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:

- (1) treating heart failure involving administration of erythropoietin and an anti-platelet drug, anti-coagulant drug, anti-thrombotic drug, anti-oxidant, anti-nitrosant, cholesterol lowering drug, aspirin or aspirin-related derivative; and
- (2) treating (T1) a myocardial infarction survivor involving continuous administration of erythropoietin in a single dose within 3 hours (preferably 1 hour, more preferably 5 minutes) of myocardial infarction.

ACTIVITY - Cardiant; Vasotropic; Cardiovascular-Gen.; Tranquilizer; Hemostatic; Antiarrhythmic; Antilipemic.

MECHANISM OF ACTION - Cardioprotective signaling pathway modulator. USE - For treating myocardial oxidative stress (caused by hypoxia or ischemia), myocardial nitrosative stress (caused by drugs, infection, inflammation, hypoxia or ischemia), cardiac injury or ischemia-reperfusion injury (e.g. myocardial infarction, cardiac arrest, ischemia-reperfusion injury, congestive heart failure, cardiotoxicity, cardiac damage due to parasitic infection, fulminant cardiac amyloidosis, heart surgery, heart transplantation, traumatic cardiac injury, surgical repair of a thoracic aortic aneurysm, suprarenal aortic aneurysm, hemorrhagic shock due to blood loss, cardiogenic shock due to myocardial infarction or cardiac failure, anaphylaxis, unstable coronary syndrome, tachycardia, bradycardia, liver, kidney, small intestine or pancreas transplant, hepatic and biliary surgical resection, total or partial pancreatectomy, total and partial pancreatectomy, total and partial pancreatectomy, esophagectomy, colorectal surgery, vascular surgery for mesenteric vascular disease, abdominal insufflation during laparoscopic surgical procedure, blunt or penetrating trauma to the abdomen including gun shot wound, stab wound, penetrating wound or blunt abdominal trauma secondary to deceleration injury or motor vehicle accident and neurogenic shock) in patients suffering from end-stage renal disease or diabetes; modulating a cardioprotective signaling pathway (e.g. MAP kinase, PI3 kinase, insulin responsive pathway, hormone, ischemia preconditioning, adenosine pathway, ras, JAK/STAT, nitric oxide synthase, hemoxygenase, xanthine

oxidase, NADPH oxidase, cytochrome p450, cytochrome p450 reductase,

oxigenase, denitrosylase, GSNO reductase, oxygen-carrying protein, nitric oxide-carrying protein, or carbon monoxide-carrying protein); preventing

organ (e.g. heart) or tissue damage during transplantation; pre-conditioning a patient at risk for a cardiac injury due to a surgical procedure; increasing and preserving beta-receptor sensitivity in a patient suffering from cardiac injury (e.g. myocardial infarction and cardiac stunning from ischemia or apoptosis); and increasing sensitivity to at least one cardiostimulatory compound (including anti-arrhythmic compound or contractility enhancing compound, e.g. dopamine, dobutamine, isoprel, digoxin, digitoxin or norepinephrine) (all claimed).

ADVANTAGE - The erythropoietin does not increase the individual's hematocrit level and does not induce red blood cell production. Dwg.0/4

L74 ANSWER 9 OF 27 USPATFULL on STN

DUPLICATE 2

ACCESSION NUMBER:

2003:140985 USPATFULL

TITLE:

Compounds useful as modulators of melanocortin

receptors and pharmaceutical compositions comprising

INVENTOR(S):

Yu, Guixue, Lawrenceville, NJ, UNITED STATES Macor, John, Guilford, CT, UNITED STATES

Herpin, Timothy, Princeton, NJ, UNITED STATES Lawrence, R. Michael, Yardley, PA, UNITED STATES Morton, George C., Collegeville, PA, UNITED STATES

Ruel, Rejean, Saint-Lambert, CANADA

Poindexter, Graham S., Old Saybrook, CT, UNITED STATES

Ruediger, Edward H., Greenfield Park, CANADA

Thibault, Carl, Mascouche, CANADA

| | NUMBER | KIND | DATE | |
|---------------------|---------------|------|----------|------|
| · | | | | |
| PATENT INFORMATION: | US 2003096827 | A1 | 20030522 | |
| | US 6713487 | B2 | 20040330 | |
| APPLICATION INFO.: | US 2002-90288 | A1 | 20020304 | (10) |

NUMBER DATE

PRIORITY INFORMATION:

______ US 2001-273206P 20010302 (60)

US 2001-273291P 20010302 (60)

DOCUMENT TYPE:

Utility

FILE SEGMENT:

APPLICATION

LEGAL REPRESENTATIVE:

STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT

DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000

NUMBER OF CLAIMS:

EXEMPLARY CLAIM:

1

2509

LINE COUNT:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Compounds having the formula (I), ##STR1##

> NR.sub.11R.sub.12; G is a novel side chain selected from C.sub.2-6alkenyl, A.sub.3-aryl, --OR.sub.18, heteroaryl, A.sub.1-cyano, A.sub.2--OR.sub.17, A.sub.1--C(.dbd.0)R.sub.18, A.sub.1--CO.sub.2R.sub.18, A.sub.1--C(.dbd.O)NR.sub.18R.sub.19, A.sub.1--OC(.dbd.O)R.sub.18, A.sub.1--NR.sub.18C(.dbd.O)R.sub.19, A.sub.1--OC(.dbd.0)NR.sub.18R.sub.19, A.sub.1--NR.sub.18CO.sub.2R.sub.19, A.sub.1--NR.sub.18SO.sub.2R.sub.17, A.sub.1--S0.sub.2R.sub.17, A.sub.1--NR.sub.20C(.dbd.0)NR.sub.18R.sub.19, and A.sub.1--SR.sub.18; or when y is 0 or when W is not NHR.sub.22, G may be A.sub.1-heterocyclo, wherein A.sub.1 is a bond, C.sub.1-6alkylene or C.sub.2-alkenylene, A.sub.2 is C.sub.1-6alkylene or C.sub.2-6alkenylene, and A.sub.3 is C.sub.2-6alkenylene; W is selected from --NR.sub.21R.sub.22, --OR.sub.23, --NR.sub.21C(.dbd.0)R.sub.24, --NR.sub.21CO.sub.2R.sub.24, amidino, guanidino, or a heteroaryl, heterocyclo or C.sub.3-7cycloalkyl as defined in the specification, and X and R.sub.1 through R.sub.24 are as defined in the specification, are effective as modulators of melanocortin-receptors, particularly MC-1R and MC-4R.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L74 ANSWER 10 OF 27 USPATFULL on STN

ACCESSION NUMBER: 2003:283209 USPATFULL

TITLE: Antidiabetic agents

INVENTOR(S): Gammill, Ronald B., East Lyme, CT, UNITED STATES

NUMBER DATE

PRIORITY INFORMATION: US 2002-360913P 20020228 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: PFIZER INC., PATENT DEPARTMENT, MS8260-1611, EASTERN

POINT ROAD, GROTON, CT, 06340

NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
LINE COUNT: 3420

PATENT INFORMATION:

APPLICATION INFO.:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound of the formula ##STR1##

wherein n, m, Z, R.sup.1, R.sup.5, R.sup.8, R.sup.9, R.sup.10 and R.sup.11 are as defined above, useful in the treatment of diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis, and tissue ischemia, particularly myocardial ischemia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L74 ANSWER 11 OF 27 USPATFULL on STN

ACCESSION NUMBER: 2003:277334 USPATFULL

TITLE: Bicyclic pyrrolyl amides as glycogen phosphorylase

inhibitors

INVENTOR(S): Du Bois, Daisy Joe, Palo Alto, CA, UNITED STATES

PATENT ASSIGNEE(S): Pfizer Inc. (U.S. corporation)

RELATED APPLN. INFO.: Division of Ser. No. US 2002-117370, filed on 5 Apr 2002, GRANTED, Pat. No. US 6576653 Division of Ser. No.

US 2000-670759, filed on 27 Sep 2000, GRANTED, Pat. No.

US 6399601

NUMBER DATE

PRIORITY INFORMATION: US 1999-157148P 19990930 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PFIZER INC.,

PFIZER INC., PATENT DEPARTMENT, MS8260-1611, EASTERN

POINT ROAD, GROTON, CT, 06340

NUMBER OF CLAIMS: 15 EXEMPLARY CLAIM: 1 LINE COUNT: 4371

LINE COUNT: 4371
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

B This invention relates to compounds of Formula I ##STR1##

or stereoisomers, pharmaceutically acceptable salts or prod rugs thereof or a pharmaceutically acceptable salts of the prodrugs. This invention also relates to pharmaceutical compositions comprising a compound of Formula I, and to methods of treatment of diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis, or tissue ischemia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L74 ANSWER 12 OF 27 USPATFULL on STN

ACCESSION NUMBER: 2003:134643

TITLE:

2003:134643 USPATFULL

Compounds useful as modulators of melanocortin

receptors and pharmaceutical compositions comprising

same

INVENTOR(S): Yu, Guixue, Lawrenceville, NJ, UNITED STATES

Macor, John, Guilford, CT, UNITED STATES
Herpin, Timothy, Princeton, NJ, UNITED STATES
Lawrence, R. Michael, Yardley, PA, UNITED STATES
Morton, George C., Collegeville, PA, UNITED STATES

Ruel, Rejean, Saint-Lambert, CANADA

Poindexter, Graham S., Old Saybrook, CT, UNITED STATES

Ruediger, Edward H., Greenfield Park, CANADA

Thibault, Carl, Mascouche, CANADA

NUMBER KIND DATE
-----US 2003092732 A1 20030515
US 2002-90582 A1 20020304 (10)

NUMBER DATE

PRIORITY INFORMATION: US 2001-273206P 20010302 (60)

US 2001-273291P 20010302 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT

DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000

NUMBER OF CLAIMS: 22 EXEMPLARY CLAIM: 1

PATENT INFORMATION: APPLICATION INFO.:

LINE COUNT: 2878

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Compounds having the formula (I), and pharmaceutically-acceptable salts,

hydrates and prodrugs thereof, ##STR1##

in which E i's

X is N or CH, W is --NR.sub.16R.sub.17, --NR.sub.16C(.dbd.0)R.sub.22, --NR.sub.16CO.sub.2R.sub.22, --OR.sub.23, or a heteroaryl or heterocyclo group as defined in the specification, and R.sub.1 through R.sub.12, R.sub.16, R.sub.17, R.sub.22, R.sub.23, x, y, and z are as defined in the specification, are useful as modulaters of melanocortin receptors, particularly MC-1R and MC-4R.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L74 ANSWER 13 OF 27 USPATFULL on STN

ACCESSION NUMBER: 2003:106714 USPATFULL

TITLE: Compositions and methods for treating peripheral

vascular disease

INVENTOR(S): Hathaway, David R., Lincoln, NE, UNITED STATES

Coolidge, Thomas R., Falls Village, CT, UNITED STATES

Continuation-in-part of Ser. No. US 2001-851738, filed RELATED APPLN. INFO.:

on 9 May 2001, PENDING Division of Ser. No. US

1999-302596, filed on 30 Apr 1999, GRANTED, Pat. No. US

6284725

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION LEGAL REPRESENTATIVE:

MCKEE, VOORHEES & SEASE, P.L.C., ATTN: BIONEBRASKA, 801

GRAND AVENUE, SUITE 3200, DES MOINES, IA, 50309-2721

NUMBER OF CLAIMS:

1

EXEMPLARY CLAIM:

LINE COUNT:

877

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

The present invention relates to methods of treating intermittent

claudication comprising administering glucagon-like

peptide-1 (GLP-1) molecules to subjects suffering therefrom.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L74 ANSWER 14 OF 27 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 3

AN TITLE: 10203424 IFIPAT; IFIUDB; IFICDB METABOLIC INTERVENTION WITH GLP-1

TO IMPROVE THE FUNCTION OF ISCHEMIC AND REPERFUSED SKELETAL MUSCLE TISSUE; CARDIOVASCULAR DISORDERS;

GLUCAGEN-LIKE PEPTIDE

INVENTOR(S):

Coolidge; Thomas R., Falls Village, CT, US

Ehlers; Mario R.W., Lincoln, NE, US

PATENT ASSIGNEE(S):

Unassigned

AGENT:

MCKEE, VOORHEES & SEASE, P.L.C. ATTN: BIONEBRASKA,

801 GRAND AVENUE, SUITE 3200, DES MOINES, IA,

50309-2721, US

NUMBER PK DATE -----US 2002147131 A1 20021010

PATENT INFORMATION: APPLICATION INFORMATION: US 2001-953021

20010911

APPLN. NUMBER DATE _______ CONTINUATION OF: US 2001-851738 DIVISION OF: US 1999-302596

20010509 PENDING 19990430 6284725

GRANTED PATENT NO.

OR STATUS

NUMBER DATE -----

PRIORITY APPLN. INFO.: FAMILY INFORMATION:

US 1998-103498P US 2002147131

19981008 (Provisional)

20021010

US 6284725

Utility

Patent Application - First Publication

FILE SEGMENT:

DOCUMENT TYPE:

CHEMICAL APPLICATION

NUMBER OF CLAIMS:

23

Individuals in need of treatment of ischemia-related reperfusion are treated, preferably intravenously, with a

composition which includes a compound which binds to a receptor for the glucagonlike peptide-1. The invention relates to both the method and

compositions for such treatment.

CLMN

L74 ANSWER 15 OF 27 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 4

NΑ 10111853 IFIPAT; IFIUDB; IFICDB TITLE: METABOLIC INTERVENTION WITH GLP-1

TO IMPROVE THE FUNCTION OF ISCHEMIC AND REPERFUSED TISSUE; ADMINSTERING A COMPOUND THAT BINDS TO A

RECEPTOR FOR THE GLUCAGON-LIKE

PEPTIDE-1 (GLP-1

INVENTOR (S):

Coolidge; Thomas R., Falls Village, CT, US

Ehlers; Mario R.W., Lincoln, NE, US

PATENT ASSIGNEE(S):

Unassigned

AGENT:

MCKEE, VOORHEES & SEASE, P.L.C. ATTN: BIONEBRASKA,

801 GRAND AVENUE, SUITE 3200, DES MOINES, IA,

50309-2721, US

NUMBER PK DATE <u>_____</u> -- -----A1 20020509 US 2002055460

PATENT INFORMATION:

20010509

APPLICATION INFORMATION: US 2001-851738

DIVISION OF:

APPLN. NUMBER _____

DATE OR STATUS -----

GRANTED PATENT NO.

19990430 6284725

US 1999-302596

NUMBER

PRIORITY APPLN. INFO.:

US 1998-103498P

_____,

19981008 (Provisional)

FAMILY INFORMATION:

US 2002055460 US 6284725

20020509

DATE

_----

DOCUMENT TYPE:

Utility

Patent Application - First Publication

FILE SEGMENT:

CHEMICAL

APPLICATION

NUMBER OF CLAIMS:

23

Individuals in need of treatment of ischemia-related

reperfusion are treated, preferably intravenously, with a

composition which includes a compound which binds to a receptor for the glucagonlike peptide-1. The invention relates to both the method and compositions for such treatment.

CLMN 23

L74 ANSWER 16 OF 27 USPATFULL on STN

DUPLICATE 5

ACCESSION NUMBER:

2002:323200 USPATFULL

TITLE:

Bicyclic pyrrolyl amides as glycogen phosphorylase

inhibitors

INVENTOR (S):

Du Bois, Daisy Joe, Palo Alto, CA, UNITED STATES

NUMBER KIND DATE -----US 2002183369 A1 20021205 PATENT INFORMATION: B2 20030610 A1 20020405 US 6576653 APPLICATION INFO.:

RELATED APPLN. INFO.:

US 2002-117370 20020405 (10)

Division of Ser. No. US 2000-670759, filed on 27 Sep 2000, GRANTED, Pat. No. US 6399601

NUMBER DATE -----

PRIORITY INFORMATION:

US 1999-157148P

19990930 (60)

DOCUMENT TYPE: FILE SEGMENT:

Utility

LEGAL REPRESENTATIVE:

APPLICATION

Gregg C. Benson, Pfizer Inc., Patent Department, MS 4159, Eastern Point Road, Groton, CT, 06340

NUMBER OF CLAIMS:

1

EXEMPLARY CLAIM:

LINE COUNT:

4347

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

This invention relates to compounds of Formula I ##STR1##

or stereoisomers, pharmaceutically acceptable salts or prodrugs thereof

or a pharmaceutically acceptable salts of the prodrugs. This invention also relates to pharmaceutical compositions comprising a compound of Formula I, and to methods of treatment of diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis, or tissue ischemia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L74 ANSWER 17 OF 27 USPATFULL on STN

DUPLICATE 6

(9)

2002:199097 USPATFULL

MITMDED

ACCESSION NUMBER:

Treatment of acute coronary syndrome with GLP

INVENTOR(S):

TITLE:

Coolidge, Thomas R., Falls Village, CT, UNITED STATES

שתעת

Ehlers, Mario, Lincoln, NE, UNITED STATES KIND

| | NUMBER | KTND | DAIR | |
|-----------------------|----------------|------|----------|--|
| | | | | |
| PATENT INFORMATION: | US 2002107206 | A1 | 20020808 | |
| • | US 6706689 | B2 | 20040316 | |
| APPLICATION INFO.: | US 2001-859804 | A1 | 20010518 | |
| IN I DI CHILION INI O | 00 2001 003001 | | | |

NUMBER DATE

PRIORITY INFORMATION:

US 2000-205239P

20000519 (60)

DOCUMENT TYPE:

Utility

FILE SEGMENT:

APPLICATION

LEGAL REPRESENTATIVE:

Beth A. Burrous, FOLEY & LARDNER, Washington Harbour,

3000 K Street, N.W. Suite 500, Washington, DC,

20007-5109

NUMBER OF CLAIMS: EXEMPLARY CLAIM:

47

AB

1

LINE COUNT:

1101

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

The invention relates to methods for treating a patient suffering from

acute coronary syndrome, but who is not suffering from a Q-wave

myocardial infarction, comprising administration of a therapeutically

effective amount of a GLP-1 molecule. The

GLP-1 can be self-administered, and can be

administered in one or more doses, as needed, on an intermittent or continuous basis, to optimize metabolism in cardiac tissue and to

prevent cardiac damage associated with ischemia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L74 ANSWER 18 OF 27 USPATFULL on STN

DUPLICATE 7

iled on 2 Dec

ACCESSION NUMBER:

TITLE:

INVENTOR(S):

2002:48618 USPATFULL

Substituted N-(indole-2-carbonyl-) amides and

derivatives as glycogen phosphorylase inhibitors

Hoover, Dennis J., Stonington, CT, UNITED STATES Hulin, Bernard, Essex, CT, UNITED STATES

Martin, William H., Essex, CT, UNITED STATES

Treadway, Judith L., Gales Ferry, CT, UNITED STATES

| | NUMBER | KIND | DATE |
|-----------------------|------------------|--------|-----------------|
| PATENT INFORMATION: | US 2002028810 | | 20020307 |
| | US 6649634 | B2 | 20031118 |
| APPLICATION INFO.: | US 2001-881136 | A1 | 20010614 (9) |
| RELATED APPLN. INFO.: | Division of Ser. | No. US | 1997-952668, f: |

1997, GRANTED, Pat. No. US 6297269 A 371 of

International Ser. No. WO 1995-IB443, filed on 6 Jun

1995, UNKNOWN

DOCUMENT TYPE: FILE SEGMENT:

Utility APPLICATION

Gregg C. Benson, Pfizer Inc., Patent Department, MS LEGAL REPRESENTATIVE:

4159,, Eastern Point Road, Groton, CT, 06340

EXEMPLARY CLAIM: LINE COUNT:

NUMBER OF CLAIMS:

4097

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

This invention relates to certain indole-2-carboxamides of formula (I) and the pharmaceutically acceptable salts and prodrugs thereof, wherein R.sub.6 is carboxy, (C.sub.1-C.sub.8) alkoxycarbonyl, C(0) NR.sub.8R.sub.9 or C(O)R.sub.12, useful as inhibitors of glycogen phosphorylase, methods of treating glycogen phosphorylase dependent diseases or conditions with such compounds and pharmaceutical compositions comprising such

compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L74 ANSWER 19 OF 27 USPATFULL on STN

ACCESSION NUMBER:

2002:194877 USPATFULL

TITLE:

Metabolic intervention with GLP-1

or its biologically active analogues to improve the

INVENTOR(S):

function of the ischemic and reperfused brain Coolidge, Thomas R., Falls Village, CT, United States

Ehlers, Mario R. W., Lincoln, NE, United States

PATENT ASSIGNEE(S):

Bionebraska, Inc., Lincoln, NE, United States (U.S.

corporation)

NUMBER KIND DATE ______

PATENT INFORMATION:

US 6429197 B1 20020806 US 1999-303016 19990430

APPLICATION INFO.:

19990430

NUMBER DATE ______

PRIORITY INFORMATION:

US 1998-103498P 19981008 (60)

DOCUMENT TYPE:

Utility

FILE SEGMENT:

GRANTED Low, Christopher S. F.

PRIMARY EXAMINER:

Mohamed, Abdel A.

ASSISTANT EXAMINER: LEGAL REPRESENTATIVE:

McKee, Voorhees & Sease, P.L.C.

NUMBER OF CLAIMS:

10

EXEMPLARY CLAIM:

1 0 Drawing Figure(s); 0 Drawing Page(s)

NUMBER OF DRAWINGS: LINE COUNT:

AΒ

643

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

It has now been discovered that GLP-1 treatment

after acute stroke or hemorrhage, preferably intravenous administration, can be an ideal treatment because it provides a means for optimizing insulin secretion, increasing brain anabolism, enhancing insulin effectiveness by suppressing glucagon, and maintaining euglycemia or mild hypoglycemia with no risk of severe hypoglycemia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L74 ANSWER 20 OF 27 USPATFULL on STN

ACCESSION NUMBER:

2002:129960 USPATFULL

TITLE:

Bicyclic pyrrolyl amides as glycogen phosphorylase

inhibitors

INVENTOR(S): PATENT ASSIGNEE(S): Du Bois, Daisy Joe, Palo Alto, CA, United States Pfizer Inc., New York, NY, United States (U.S.

corporation)

NUMBER KIND DATE -----US 6399601 B1 20020604 US 2000-670759 20000927 (9)

PATENT INFORMATION: APPLICATION INFO.:

DATE NUMBER

PRIORITY INFORMATION: US 1999-157148P 19990930 (60)

DOCUMENT TYPE: Utility GRANTED FILE SEGMENT:

PRIMARY EXAMINER: Ramsuer, Robert W.

ASSISTANT EXAMINER: Wright, Sonya LEGAL REPRESENTATIVE: Richardson, Peter C., Benson, Gregg C., Crissey, Todd

14

NUMBER OF CLAIMS: EXEMPLARY CLAIM:

AB

1 NUMBER OF DRAWINGS:

0 Drawing Figure(s); 0 Drawing Page(s)

LINE COUNT:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

This invention relates to compounds of Formula I ##STR1##

or stereoisomers, pharmaceutically acceptable salts or prodrugs thereof or a pharmaceutically acceptable salts of the prodrugs. This invention also relates to pharmaceutical compositions comprising a compound of Formula I, and to methods of treatment of diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis, or tissue ischemia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 21 OF 27 USPATFULL on STN

ACCESSION NUMBER: 2001:168152 USPATFULL

Substituted n-(indole-2-carbonyl-) amides and TITLE:

derivatives as glycogen phosphorylase inhibitors

Hulin, Bernard, Essex, CT, United States INVENTOR(S):

> Hoover, Dennis J., Stonington, CT, United States Treadway, Judith L., Gales Ferry, CT, United States

Martin, William H., Essex, CT, United States

Pfizer Inc., New York, NY, United States (U.S. PATENT ASSIGNEE(S):

corporation)

| | NUMBER | KIND | DATE | |
|---------------------|----------------|------|----------|-----------------|
| | | | | |
| PATENT INFORMATION: | US 6297269 | B1 | 20011002 | |
| | WO 9639385 | | 19961212 | |
| APPLICATION INFO.: | US 1997-952668 | | 19971202 | (8) |
| | WO 1995-IB443 | | 19950606 | |
| | | | 19971202 | PCT 371 date |
| | | | 19971202 | PCT 102(e) date |
| DOCUMENT TYPE: | Utility | | | |

FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Ramsuer, Robert W. Keating, Domenik ASSISTANT EXAMINER:

LEGAL REPRESENTATIVE: Richardson, Peter C., Benson, Gregg C., Olson, A. Dean

NUMBER OF CLAIMS: 77 EXEMPLARY CLAIM: 1 LINE COUNT: 4318

AB

CAS INDEXING IS AVAILABLE FOR THIS PATENT. Compounds of the formula I: ##STR1##

and their compositions are useful as glycogen phosphorylase inhibitors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L74 ANSWER 22 OF 27 USPATFULL on STN

ACCESSION NUMBER: 2001:147933 USPATFULL

TITLE: Metabolic intervention with GLP-1

to improve the function of ischemic and reperfused

tissue

INVENTOR(S):

Coolidge, Thomas R., Falls Village, CT, United States

Ehlers, Mario R. W., Lincoln, NE, United States

PATENT ASSIGNEE(S):

BioNebraska, Inc., Lincoln, NE, United States (U.S.

corporation)

NUMBER KIND DATE ______

PATENT INFORMATION:

US 6284725 B1 20010904

US 1999-302596 APPLICATION INFO.:

19990430 (9)

DATE NUMBER _____

PRIORITY INFORMATION:

US 1998-103498P 19981008 (60)

DOCUMENT TYPE:

Utility

FILE SEGMENT:

GRANTED

PRIMARY EXAMINER:

Davenport, Avis M.

LEGAL REPRESENTATIVE:

Zarley, McKee, Thomte, Voorhees & Sease

NUMBER OF CLAIMS:

13 1

EXEMPLARY CLAIM:

LINE COUNT:

650

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Individuals in need of treatment of ischemia-related

reperfusion are treated, preferably intravenously, with a

composition which includes a compound which binds to a receptor for the

glucagon-like peptide-1. The

invention relates to both the method and compositions for such

treatment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L74 ANSWER 23 OF 27 USPATFULL on STN

ACCESSION NUMBER:

2001:136680 USPATFULL

TITLE:

Substituted n-(indole-2-carbonyl)glycinamides and derivates as glycogen phosphorylase inhibitors

INVENTOR (S):

Hoover, Dennis J., Stonington, CT, United States

Hulin, Bernard, Essex, CT, United States Martin, William H., Essex, CT, United States Phillips, Douglas, Gales Ferry, CT, United States Treadway, Judith L., Gales Ferry, CT, United States

PATENT ASSIGNEE(S):

Pfizer, Inc., New York, NY, United States (U.S.

corporation)

NUMBER KIND DATE -----

PATENT INFORMATION:

APPLICATION INFO.:

RELATED APPLN. INFO.:

US 6277877 B1 20010821 US 2000-638938 20000815 20000815 (9)

Division of Ser. No. US 952669, now patented, Pat. No. US 6107329, issued on 22 Aug 2000

DOCUMENT TYPE:

Utility GRANTED

FILE SEGMENT: PRIMARY EXAMINER:

Riley, Jezia

LEGAL REPRESENTATIVE:

Richardson, Peter C., Benson, Gregg C., Olson, A. Dean

NUMBER OF CLAIMS:

EXEMPLARY CLAIM:

1 5510

LINE COUNT:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Compounds of Formula (I) ##STR1##

wherein

R.sub.6 is carboxy, (C.sub.1 -C.sub.8) alkoxycarbonyl, benzyloxycarbonyl, C(0) NR.sub.8 R.sub.9 or C(0) R.sub.12 as glycogen phosphorylase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperisulinemia, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L74 ANSWER 24 OF 27 USPATFULL on STN

ACCESSION NUMBER:

2000:109834 USPATFULL

TITLE:

Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors

INVENTOR (S):

Hoover, Dennis J., Stonington, CT, United States

Hulin, Bernard, Essex, CT, United States Martin, William H., Essex, CT, United States Phillips, Douglas, Gales Ferry, CT, United States Treadway, Judith L., Gales Ferry, CT, United States

PATENT ASSIGNEE(S):

Pfizer, Inc., New York, NY, United States (U.S.

corporation)

| | NUMBER | KIND DATE | |
|---------------------|----------------|-----------|-------------------|
| | | | |
| PATENT INFORMATION: | US 6107329 | 20000822 | |
| | WO 9639384 | 19961212 | |
| APPLICATION INFO.: | US 1997-952669 | 19971202 | (8) |
| | WO 1995-IB442 | 19950606 | |
| | | 19971202 | PCT 371 date |
| | | 19971202 | PCT 102(e) date |
| | | 200,2202 | - 01 101 (0) aacc |

DOCUMENT TYPE: FILE SEGMENT:

Utility Granted Riley, Jezia

PRIMARY EXAMINER: LEGAL REPRESENTATIVE:

Richardson, Peter C., Benson, Gregg C., Olson, A. Dean

NUMBER OF CLAIMS: EXEMPLARY CLAIM:

44 1 5662

LINE COUNT:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AR

Compounds of Formula (1) wherein R.sub.6 is carboxy, (C.sub.1 -C.sub.8) alkoxycarbonyl, benzyloxycarbonyl, C(0) NR.sub.8 R.sub.9 or C(O)R.sub.12 as glucogen phosphorylase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L74 ANSWER 25 OF 27

WPIDS COPYRIGHT 2004 THE THOMSON CORP on STN

ACCESSION NUMBER:

2001-015911 [02] WPIDS

CROSS REFERENCE:

2001-040881 [05]; 2002-739470 [80]; 2003-677986 [64]

DOC. NO. CPI:

C2001-004338

TITLE:

A method for amelioration of brain tissue injury comprises administering a composition including a compound which binds to a receptor for glucagon

-like peptide-1.

DERWENT CLASS:

INVENTOR (S):

COOLIDGE, T R; EHLERS, M R W

PATENT ASSIGNEE(S):

(BION-N) BIONEBRASKA INC; (AMYL-N) AMYLIN PHARM INC

COUNTRY COUNT:

PATENT INFORMATION:

| PATENT | NO | KIND | DATE | WEEK | LA | PG |
|--------|----|------|------|------|----|----|
| | | | | | | |

WO 2000066142 A2 20001109 (200102)* EN 17

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ TZ UG ZW

W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

20001117 (200111) AU 2000046825 Α

NO 2001005298 A 20011228 (200221) EP 1187628 A2 20020320 (200227) EN

R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT

25

RO SE SI

JP 2002543145 W 20021217 (200312)

MX 2001010937 A1 20020601 (200365)

NZ 514609 A 20040326 (200425)

APPLICATION DETAILS:

| PATENT NO | KIND | APPLICATION | DATE |
|---------------|------|-----------------|----------|
| WO 2000066142 | A2 | WO 2000-US11652 | 20000501 |
| AU 2000046825 | A | AU 2000-46825 | 20000501 |
| NO 2001005298 | A | WO 2000-US11652 | 20000501 |
| | | NO 2001-5298 | 20011029 |
| EP 1187628 | A2 | EP 2000-928616 | 20000501 |
| | | WO 2000-US11652 | 20000501 |
| JP 2002543145 | W . | JP 2000-615026 | 20000501 |
| | | WO 2000-US11652 | 20000501 |
| CN 1376072 | A | CN 2000-806935 | 20000501 |
| MX 2001010937 | A1 | WO 2000-US11652 | 20000501 |
| | | MX 2001-10937 | 20011026 |
| NZ 514609 | A | NZ 2000-514609 | 20000501 |
| | | WO 2000-US11652 | 20000501 |
| | | | |

FILING DETAILS:

| PATENT NO | | KIND | | | PATENT NO | | |
|-----------|----|------------|----|-------|-----------|----|------------|
| | AU | 2000046825 | A | Based | on | WO | 2000066142 |
| | ΕP | 1187628 | A2 | Based | on | WO | 2000066142 |
| | JP | 2002543145 | W | Based | on | WO | 2000066142 |
| | MX | 2001010937 | A1 | Based | on | WO | 2000066142 |
| | NZ | 514609 | Α | Based | on | WO | 2000066142 |

PRIORITY APPLN. INFO: US 1999-303016

AN 2001-015911 [02] WPIDS

CR 2001-040881 [05]; 2002-739470 [80]; 2003-677986 [64]

AB WO 200066142 A UPAB: 20040418

NOVELTY - A method for amelioration of brain tissue injury caused by reperfusion of blood flow comprises administering a composition including a compound which binds to a receptor for glucagon-like peptide-1 (GLP-1), in

a pharmaceutical carrier.

ACTIVITY - Vasotropic; cerebroprotective.

No biological data is given.

MECHANISM OF ACTION - Stimulates endogenous insulin secretion.

19990430

USE - The method is used for amelioration of brain tissue injury caused by **reperfusion** of blood flow following a period of **ischemia** (claimed). **GLP-1** is used for

metabolic intervention to improve the function of ischemic and reperfused brain cells (claimed). It treats patients after an acute stroke or hemorrhage and **tissue damage** arising from a medical

procedure that is a surgical event causing **ischemia** of brain tissue or a medical procedure involving a **reperfusion** event.

ADVANTAGE - GLP-1 is an ideal alternative to insulin for the treatment of stroke as it stimulates endogenous insulin secretion in the presence of normo- to hyperglycemia but not during hypoglycemia, thus protecting against the development of severe hypoglycemia. The treatment optimizes insulin secretion, increases brain anabolism, enhancing insulin effectiveness by suppressing glucagon and maintains euglycemia or mild hypoglycemia with no risk of severe hypoglycemia.

Dwq.0/0

L74 ANSWER 26 OF 27 WPIDS COPYRIGHT 2004 THE THOMSON CORP on STN

ACCESSION NUMBER: 2001-040881 [05] WPIDS

2001-015911 [02]; 2002-739470 [80]; 2003-677986 [64]

DOC. NO. CPI: C2001-011804

TITLE: Metabolic intervention with GLP-1

improves function of ischemic and reperfused tissue.

26

DERWENT CLASS: B04

INVENTOR(S): COOLIDGE, T R; EHLERS, M R W

JP 2002543142 W 20021217 (200312)

MX 2001010859 A1 20020601 (200365)

PATENT ASSIGNEE(S): (BION-N) BIONEBRASKA INC; (COOL-I) COOLIDGE T R; (EHLE-I)

EHLERS M R W

COUNTRY COUNT: 9:

PATENT INFORMATION:

CROSS REFERENCE:

| PAT | rent | ИО | | | KI | ND I | ITAC | Ξ | Ī | VEE1 | C | | LA | I | PG | | | | | | | | |
|---------------|---------------|---------------|------|-------|------------|---------------|------|-----|------|------|------|------------------------|----------|----|----|------------|----|----|----|----|----|------------------------|---------------|
| WO | 2000 | 0066 | 5138 | 3 | A2 | 200 | 001 | L09 | (20 | 0010 |)5); | E | 1 | 22 | - | | | | | | | | |
| | RW: | \mathbf{AT} | BE | CH | CY | DE | DK | EA | ES | FI | FR | GB | GH | GM | GR | ΙE | IT | ΚE | LS | LU | MC | MW | NL |
| | | ΟA | PT | SD | SE | \mathtt{SL} | SZ | TZ | UG | ZW | | | | | | | | | | | | | |
| | W: | ΑE | AL | MΑ | ΑT | AU | AZ | BA | BB | BG | BR | $\mathbf{B}\mathbf{Y}$ | CA | CH | CN | CR | CU | CZ | DE | DK | DM | $\mathbf{E}\mathbf{E}$ | ES |
| | | | GB | | | | | | | | | | | | | | | | | | | | |
| | | $_{ m LT}$ | LU | LV | MA | MD | MG | MK | MN | MW | MX | NO | NZ | PL | PT | RO | RU | SD | SE | SG | SI | SK | \mathtt{SL} |
| | | TJ | TM | TR | TT | TZ | UA | UG | UZ | VN | ΥU | ZA | zw | | | | | | | | | | |
| AU 2000044935 | | | Α | 200 | 001 | 117 | (2) | 001 | 11) | | | | | | | | | | | | | | |
| US | 6284 | 472 | 5 | | В1 | 200 | 010 | 904 | (2) | 0016 | 53) | , | | 10 | | | | | | | | | |
| ΕP | 1173 | 319 | 7 | | A2 | 200 | 020 | 123 | (2 | 002 | L4) | El | Ŋ | | | | | | | | | | |
| | R: | AL | AT | BE | CH | CY | DE | DK | ES | FI | FR | GB | GR | ΙE | IT | $_{ m LI}$ | LT | LU | LV | MC | MK | NL | PT |
| | | RO | SE | sI | | | | | | | | | | | | | | | | | | | |
| ИО | 200 | 100! | 5294 | 1 | Α | 200 | 0112 | 228 | (2 | 0022 | 21) | | | | | | | | | | | | |
| US | 200 | 205 | 5460 |) | A1 | 200 | 020! | 509 | (2) | 0025 | 50) | | | 8 | | | | | | | | | |
| CN | CN 1349409 | | | Α | 20 | 020 | 515 | (2) | 0026 | 50) | | | | | | | | | | | | | |
| NZ | NZ 514610 | | | | Α | 20 | 020 | 927 | (2 | 002 | 72) | | | | | | | | | | | | |
| US | JS 2002147131 | | | 1 | A 1 | 20 | 021 | 010 | (2 | 002 | 74) | | | | | | | | | | | | |

APPLICATION DETAILS:

| PATENT NO | KIND | APPLICATION | DATE | | | |
|---------------|----------------|-----------------|----------|--|--|--|
| WO 2000066138 | A2 | WO 2000-US11251 | | | | |
| AU 2000044935 | Α | AU 2000-44935 | 20000427 | | | |
| US 6284725 | B1 Provisional | US 1998-103498P | 19981008 | | | |
| | | US 1999-302596 | 19990430 | | | |
| EP 1173197 | A2 | EP 2000-926404 | 20000427 | | | |
| | | WO 2000-US11251 | 20000427 | | | |
| NO 2001005294 | Α | WO 2000-US11251 | 20000427 | | | |
| | | NO 2001-5294 | 20011029 | | | |
| US 2002055460 | A1 Provisional | US 1998-103498P | 19981008 | | | |
| | Div ex | US 1999-302596 | 19990430 | | | |
| | | US 2001-851738 | 20010509 | | | |
| CN 1349409 | A | CN 2000-806951 | 20000427 | | | |
| NZ 514610 | A | NZ 2000-514610 | 20000427 | | | |
| | | WO 2000-US11251 | 20000427 | | | |
| US 2002147131 | Al Provisional | US 1998-103498P | 19981008 | | | |
| | Div ex | US 1999-302596 | 19990430 | | | |
| | Cont of | US 2001-851738 | 20010509 | | | |
| | | US 2001-953021 | 20010911 | | | |
| JP 2002543142 | W | JP 2000-615022 | 20000427 | | | |
| | | WO 2000-US11251 | 20000427 | | | |
| MX 2001010859 | A1 | WO 2000-US11251 | 20000427 | | | |
| | • | MX 2001-10859 | 20011025 | | | |

FILING DETAILS:

| PATENT NO | KIND | PATENT NO |
|-----------|------|-----------|
| | | |

AU 2000044935 A Based on WO 2000066138 A2 Based on WO 2000066138 EP 1173197 Al Div ex US 6284725 US 2002055460 WO 2000066138 A Based on NZ 514610 A1 Div ex US 6284725 US 2002147131 W Based on WO 2000066138 JP 2002543142 MX 2001010859 A1 Based on WO 2000066138

PRIORITY APPLN. INFO: US 1999-302596 19990430; US

19981008; US 1998-103498P 2001-851738 20010509; US 2001-953021 20010911

AN2001-040881 [05] WPIDS

AB

2001-015911 [02]; 2002-739470 [80]; 2003-677986 [64] CR

WO 200066138 A UPAB: 20031009

NOVELTY - Metabolic intervention with GLP-1 improves function of ischemic and reperfused tissue.

DETAILED DESCRIPTION - A method for amelioration of organ tissue caused by reperfusion of blood flow following a period of ischemia comprises administering a composition including a compound which binds to a receptor for glucagon-like peptide-1 (GLP-1), in a carrier.

INDEPENDENT CLAIMS are also included for:

- (1) a method of metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue, the method comprising administering a composition comprising GLP-1 in a carrier; and
- (2) a composition for use in the metabolic intervention with GLP-1 as above.

USE - The method is useful after surgical procedures selected from cardiac surgical procedures, organ transplants, traumatic limb amputation and reattachment, a ischemic reperfusion event concurrent with gut infarct and myocardial infarct and improves the function of ischemic and reperfused tissues.

ADVANTAGE - The method is devoid of side effects associated with current procedures. Antiquenic and immune stimulating properties are not adversely affected.

Dwg.0/0

L74 ANSWER 27 OF 27 USPATFULL on STN

ACCESSION NUMBER:

PATENT ASSIGNEE(S):

1999:160079 USPATFULL

TITLE: INVENTOR(S): Glycogen phosphorylase inhibitors

Hulin, Bernard, Essex, CT, United States

Sarges, Reinhard, Mystic, CT, United States

Pfizer Inc, New York, NY, United States (U.S.

corporation)

NUMBER KIND -----US 5998463 19991207 US 1999-251141 19990216 (9)

PATENT INFORMATION: APPLICATION INFO.:

> NUMBER DATE

PRIORITY INFORMATION:

DOCUMENT TYPE:

US 1998-76132P Utility

19980227 (60)

FILE SEGMENT:

Granted

PKIMAKY EXAMINER:
ASSISTANT EXAMINER: PRIMARY EXAMINER:

Richter, Johann

Keating, Dominic

LEGAL REPRESENTATIVE:

Richardson, Peter C., Benson, Gregg C., Gammill, Martha

Α.

NUMBER OF CLAIMS: EXEMPLARY CLAIM:

23

LINE COUNT:

1

1835

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

This invention relates to certain 5-acyl-2-oxo-indole-3-carboxamides

useful as inhibitors of glycogen phosphorylase, methods of treating glycogen phosphorylase dependent diseases or conditions with such compounds and pharmaceutical compositions comprising such compounds. This invention also relates to pharmaceutical compositions comprising those 5-acyl-2-oxo-indole-3-carboxamides in combination with antidiabetes agents and methods of treating glycogen phosphorylase dependent diseases or conditions with such compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.